QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
BERMUDA | N/A | ||||
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
Title of Each Class | Trading Symbol(s) | Name of Each Exchange on Which Registered | |||||||||
Ordinary shares, par value $1.00 per share | ESGR | The NASDAQ Stock Market | LLC | ||||||||
Depositary Shares, Each Representing a 1/1,000th Interest in a 7.00% | ESGRP | The NASDAQ Stock Market | LLC | ||||||||
Fixed-to-Floating Rate Perpetual Non-Cumulative Preferred Share, Series D, Par Value $1.00 Per Share | |||||||||||
Depositary Shares, Each Representing a 1/1,000th Interest in a 7.00% | ESGRO | The NASDAQ Stock Market | LLC | ||||||||
Perpetual Non-Cumulative Preferred Share, Series E, Par Value $1.00 Per Share |
Large accelerated filer | ☒ | Accelerated filer | ☐ | Non-accelerated filer | ☐ | Smaller reporting company | ☐ | Emerging growth company | ☐ |
Page | ||||||||
PART I | ||||||||
Item 1. | ||||||||
Item 2. | ||||||||
Item 3. | ||||||||
Item 4. | ||||||||
PART II | ||||||||
Item 1. | ||||||||
Item 1A. | ||||||||
Item 2. | ||||||||
Item 3. | ||||||||
Item 4. | ||||||||
Item 5. | ||||||||
Item 6. |
A&E | Asbestos and environmental | |||||||
Acquisition costs | Costs that are directly related to the successful efforts of acquiring new insurance contracts or renewing existing insurance contracts, and which principally consist of incremental costs such as: commissions, brokerage expenses, premium taxes and other fees incurred at the time that a contract or policy is issued. | |||||||
ADC | Adverse development cover – A retrospective reinsurance arrangement that will insure losses in excess of an established reserve and provide protection up to a contractually agreed amount. | |||||||
Adjusted RLE | Adjusted run-off liability earnings - Non-GAAP financial measure calculated by dividing adjusted prior period development by average adjusted net loss reserves. See “Non-GAAP Financial Measures” for reconciliation. | |||||||
Adjusted ROE | Adjusted return on equity - Non-GAAP financial measure calculated by dividing adjusted operating income (loss) attributable to Enstar ordinary shareholders by adjusted opening Enstar ordinary shareholders’ equity. See “Non-GAAP Financial Measures” for reconciliation. | |||||||
Adjusted TIR | Adjusted total investment return - Non-GAAP financial measure calculated by dividing adjusted total investment return by average adjusted total investable assets. See “Non-GAAP Financial Measures” for reconciliation. | |||||||
AFS | Available-for-sale | |||||||
Allianz | Allianz SE | |||||||
AmTrust | AmTrust Financial Services, Inc. | |||||||
Annualized | Calculation of the quarterly result or year-to-date result multiplied by four and then divided by the number of quarters elapsed within the applicable year-to-date period. | |||||||
AOCI | Accumulated other comprehensive income | |||||||
APIC | Additional Paid-in Capital | |||||||
ASC | Accounting Standards Codification | |||||||
ASU | Accounting Standards Update | |||||||
Arden | Arden Reinsurance Company Ltd. | |||||||
Atrium | Atrium Underwriting Group Limited | |||||||
bps | Basis point(s) | |||||||
BMA | Bermuda Monetary Authority | |||||||
BSCR | Bermuda Solvency Capital Requirement | |||||||
BVPS | Book value per ordinary share - GAAP financial measure calculated by dividing Enstar ordinary shareholders’ equity by the number of ordinary shares outstanding. | |||||||
Cavello | Cavello Bay Reinsurance Limited, a wholly-owned subsidiary | |||||||
Citco | Citco III Limited | |||||||
CLO | Collateralized loan obligation | |||||||
Core Specialty | Core Specialty Insurance Holdings, Inc. | |||||||
DCo | DCo LLC | |||||||
Defendant A&E liabilities | Defendant asbestos and environmental liabilities - Non-insurance liabilities relating to amounts for indemnity and defense costs for pending and future claims, as well as amounts for environmental liabilities associated with properties. | |||||||
DCA | Deferred charge asset - The amount by which estimated ultimate losses payable exceed the consideration received at the inception of a retroactive reinsurance agreement and that are subsequently amortized over the estimated loss settlement period. | |||||||
DGL | Deferred gain liability - The amount by which consideration received exceeds estimated ultimate losses payable at the inception of a retroactive reinsurance agreement and that are subsequently amortized over the estimated loss settlement period. | |||||||
EB Trust | Enstar Group Limited Employee Benefit Trust | |||||||
Enhanzed Re | Enhanzed Reinsurance Ltd. | |||||||
Enstar | Enstar Group Limited and its consolidated subsidiaries |
Enstar Finance | Enstar Finance LLC | |||||||
Exchange Transaction | The exchange of a portion of our indirect interest in Northshore for all of the Trident V Funds’ indirect interest in StarStone U.S. | |||||||
FAL | Funds at Lloyd's - A deposit in the form of cash, securities, letters of credit or other approved capital instrument that satisfies the capital requirement to support the Lloyd's syndicate underwriting capacity. | |||||||
FDBVPS | Fully diluted book value per ordinary share - Non-GAAP financial measure calculated by dividing Enstar ordinary shareholders’ equity by the number of ordinary shares outstanding, adjusted for equity awards granted and not yet vested (similar to the calculation of diluted earnings per share). See “Non-GAAP Financial Measures” in Item 7 for reconciliation. | |||||||
Funds held | The account created with premium due to the reinsurer pursuant to the reinsurance agreement, the balance of which is credited with investment income and losses paid are deducted. | |||||||
Funds held by reinsured companies | Funds held, as described above, where we receive a fixed crediting rate of return or other contractually agreed return on the assets held. | |||||||
Funds held - directly managed | Funds held, as described above, where we receive the actual investment portfolio return on the assets held. | |||||||
Future policyholder benefits | The liability relating to life reinsurance contracts, which are based on the present value of anticipated future cash flows and mortality rates. | |||||||
IBNR | Incurred but not reported - The estimated liability for unreported claims that have been incurred, as well as estimates for the possibility that reported claims may settle for amounts that differ from the established case reserves as well as the potential for closed claims to re-open. | |||||||
Investable assets | The sum of total investments, cash and cash equivalents, restricted cash and cash equivalents and funds held | |||||||
JSOP | Joint Share Ownership Plan | |||||||
LAE | Loss adjustment expenses | |||||||
Lloyd's | This term may refer to either the society of individual and corporate underwriting members that pool and spread risks as members of one or more syndicates, or the Corporation of Lloyd’s, which regulates and provides support services to the Lloyd’s market | |||||||
LOC | Letters of credit | |||||||
LPT | Loss Portfolio Transfer - Retroactive reinsurance transaction in which loss obligations that are already incurred are ceded to a reinsurer, subject to any stipulated limits | |||||||
Monument Midco | Monument Midco Limited, a wholly owned subsidiary of Monument Re | |||||||
Monument Re | Monument Insurance Group Limited | |||||||
Morse TEC | Morse TEC LLC | |||||||
NAV | Net asset value | |||||||
NCI | Noncontrolling interests | |||||||
New business | Material transactions, which generally take the form of reinsurance or direct business transfers, or business acquisitions. | |||||||
Northshore | Northshore Holdings Limited | |||||||
OLR | Outstanding loss reserves - Provisions for claims that have been reported and accrued but are unpaid at the balance sheet date. | |||||||
Parent Company | Enstar Group Limited, excluding its consolidated subsidiaries | |||||||
pp | Percentage point(s) | |||||||
PPD | Prior period development - Changes to loss estimates recognized in the current calendar year that relate to loss reserves established in previous calendar years. | |||||||
Private equity funds | Investments in limited partnerships and limited liability companies | |||||||
QBE | QBE Insurance Group Limited | |||||||
RACQ | RACQ Insurance Limited | |||||||
Reinsurance to close (RITC) | A business transaction to transfer estimated future liabilities attached to a given year of account of a Lloyd's syndicate into a later year of account of either the same or different Lloyd's syndicate in return for a premium. | |||||||
Reserves for losses and LAE | Management's best estimate of the ultimate cost of settling losses as of the balance sheet date. This includes OLR and IBNR. | |||||||
Retroactive reinsurance | Contracts that provide indemnification for losses and LAE with respect to past loss events. | |||||||
RLE | Run-off liability earnings – GAAP-based financial measure calculated by dividing prior period development by average net loss reserves. | |||||||
RNCI | Redeemable noncontrolling interests | |||||||
ROE | Return on equity - GAAP-based financial measure calculated by dividing net income (loss) attributable to Enstar ordinary shareholders by opening Enstar ordinary shareholders’ equity | |||||||
Run-off | A line of business that has been classified as discontinued by the insurer that initially underwrote the given risk | |||||||
Run-off portfolio | A group of insurance policies classified as run-off. | |||||||
SEC | U.S. Securities and Exchange Commission | |||||||
SGL No. 1 | SGL No. 1 Limited | |||||||
StarStone International | StarStone's non-U.S. operations | |||||||
StarStone U.S. | StarStone U.S. Holdings, Inc. and its subsidiaries | |||||||
Stone Point | Stone Point Capital LLC | |||||||
TIR | Total investment return - GAAP financial measure calculated by dividing total investment return, including other comprehensive income, for the applicable period by average total investable assets | |||||||
Trident V Funds | Trident V, L.P., Trident V Parallel Fund, L.P. and Trident V Professionals Fund, L.P. | |||||||
U.S. GAAP | Accounting principles generally accepted in the United States of America | |||||||
ULAE | Unallocated loss adjustment expenses - Loss adjustment expenses relating to run-off costs for the estimated payout of the run-off, such as internal claim management or associated operational support costs. | |||||||
Unearned premium | The unexpired portion of policy premiums that will be earned over the remaining term of the insurance contract. | |||||||
VIE | Variable interest entities | |||||||
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS | Page | ||||
Unaudited Condensed Consolidated Statements of Operations for the three months ended March 31, 2024 and 2023 | |||||
Unaudited Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2024 and 2023 | |||||
Three Months Ended March 31, | |||||||||||
2024 | 2023 | ||||||||||
(expressed in millions of U.S. dollars, except share and per share data) | |||||||||||
REVENUES | |||||||||||
Net premiums earned | $ | 11 | $ | 8 | |||||||
Net investment income | 160 | 156 | |||||||||
Net realized losses | (6) | (18) | |||||||||
Fair value changes in trading securities, funds held and other investments | 85 | 206 | |||||||||
Other income | — | 280 | |||||||||
Total revenues | 250 | 632 | |||||||||
EXPENSES | |||||||||||
Net incurred losses and loss adjustment expenses | |||||||||||
Current period | 5 | 10 | |||||||||
Prior periods | (24) | (10) | |||||||||
Total net incurred losses and loss adjustment expenses | (19) | — | |||||||||
Amortization of net deferred charge assets | 30 | 17 | |||||||||
Acquisition costs | 1 | 2 | |||||||||
General and administrative expenses | 87 | 89 | |||||||||
Interest expense | 22 | 23 | |||||||||
Net foreign exchange gains | (9) | (6) | |||||||||
Total expenses | 112 | 125 | |||||||||
INCOME BEFORE INCOME TAXES | 138 | 507 | |||||||||
Income tax (expense) benefit | (5) | 1 | |||||||||
(Loss) income from equity method investments | (5) | 11 | |||||||||
NET INCOME | 128 | 519 | |||||||||
Net income attributable to noncontrolling interests | — | (86) | |||||||||
NET INCOME ATTRIBUTABLE TO ENSTAR | 128 | 433 | |||||||||
Dividends on preferred shares | (9) | (9) | |||||||||
NET INCOME ATTRIBUTABLE TO ENSTAR ORDINARY SHAREHOLDERS | $ | 119 | $ | 424 | |||||||
Earnings per ordinary share attributable to Enstar Ordinary Shareholders: | |||||||||||
Basic | $ | 8.13 | $ | 24.97 | |||||||
Diluted | $ | 8.02 | $ | 24.79 | |||||||
Weighted average ordinary shares outstanding: | |||||||||||
Basic | 14,641,158 | 16,980,240 | |||||||||
Diluted | 14,833,840 | 17,100,954 | |||||||||
Three Months Ended March 31, | |||||||||||
2024 | 2023 | ||||||||||
(expressed in millions of U.S. dollars) | |||||||||||
NET INCOME | $ | 128 | $ | 519 | |||||||
Other comprehensive income (loss), net of income taxes: | |||||||||||
Unrealized (losses) gains on fixed maturities, available-for-sale arising during the period | (33) | 57 | |||||||||
Reclassification adjustment for change in allowance for credit losses recognized in net income | 1 | (9) | |||||||||
Reclassification adjustment for net realized losses included in net income | 5 | 27 | |||||||||
Unrealized (losses) gains arising during the period, net of reclassification adjustments | (27) | 75 | |||||||||
Reclassification adjustment for remeasurement of future policyholder benefits included in net income | — | (363) | |||||||||
Change in currency translation adjustment | (1) | 5 | |||||||||
Total other comprehensive loss | (28) | (283) | |||||||||
Comprehensive income | 100 | 236 | |||||||||
Comprehensive loss attributable to noncontrolling interests | — | 3 | |||||||||
COMPREHENSIVE INCOME ATTRIBUTABLE TO ENSTAR | $ | 100 | $ | 239 |
Share Capital | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Non-voting Convertible Ordinary Shares | Preferred Shares | Treasury Shares | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Voting Ordinary Shares | Series C | Series E | Series C Convertible Participating Non-Voting | Series D | Series E | Series C Preferred Shares | JSOP | APIC | AOCI | Retained Earnings | Total Enstar Shareholders' Equity | NCI | Total Shareholders' Equity | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(in millions of U.S. dollars) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Three Months Ended March 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance as at December 31, 2023 | $ | 15 | $ | — | $ | — | $ | — | $ | 400 | $ | 110 | $ | (422) | $ | (1) | $ | 579 | $ | (336) | $ | 5,190 | $ | 5,535 | $ | 113 | $ | 5,648 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Net income attributable to Enstar or noncontrolling interests | — | — | — | — | — | — | — | — | — | — | 128 | 128 | — | 128 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dividends on preferred shares | — | — | — | — | — | — | — | — | — | — | (9) | (9) | — | (9) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Amortization of share-based compensation | — | — | — | — | — | — | — | — | 8 | — | — | 8 | — | 8 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other comprehensive loss, net of tax | — | — | — | — | — | — | — | — | — | (28) | — | (28) | — | (28) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other | — | — | — | — | — | — | — | — | (2) | — | — | (2) | 1 | (1) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance as at March 31, 2024 | $ | 15 | $ | — | $ | — | $ | — | $ | 400 | $ | 110 | $ | (422) | $ | (1) | $ | 585 | $ | (364) | $ | 5,309 | $ | 5,632 | $ | 114 | $ | 5,746 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Three Months Ended March 31, 2023 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance as at December 31, 2022 | $ | 16 | $ | 1 | $ | — | $ | — | $ | 400 | $ | 110 | $ | (422) | $ | (1) | $ | 766 | $ | (302) | $ | 4,406 | $ | 4,974 | $ | 186 | $ | 5,160 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Net income attributable to Enstar or noncontrolling interests | — | — | — | — | — | — | — | — | — | — | 433 | 433 | 85 | 518 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dividends on preferred shares | — | — | — | — | — | — | — | — | — | — | (9) | (9) | — | (9) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Ordinary shares repurchased | — | (1) | — | — | — | — | — | — | (339) | — | — | (340) | — | (340) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Amortization of share-based compensation | — | — | — | — | — | — | — | — | 6 | — | — | 6 | — | 6 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Acquisition of noncontrolling shareholders' interest in subsidiary | — | — | — | — | — | — | — | — | 9 | — | — | 9 | (174) | (165) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other comprehensive loss, net of tax | — | — | — | — | — | — | — | — | — | (194) | — | (194) | (90) | (284) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other | — | — | — | — | — | — | — | — | (2) | — | — | (2) | — | (2) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance as at March 31, 2023 | $ | 16 | $ | — | $ | — | $ | — | $ | 400 | $ | 110 | $ | (422) | $ | (1) | $ | 440 | $ | (496) | $ | 4,830 | $ | 4,877 | $ | 7 | $ | 4,884 |
Three Months Ended March 31, | |||||||||||
2024 | 2023 | ||||||||||
(expressed in millions of U.S. dollars) | |||||||||||
OPERATING ACTIVITIES: | |||||||||||
Net income | $ | 128 | $ | 519 | |||||||
Adjustments to reconcile net income to cash flows provided by operating activities: | |||||||||||
Realized losses on investments | 6 | 18 | |||||||||
Fair value changes in trading securities, funds held and other investments | (85) | (206) | |||||||||
Amortization of net deferred charge assets | 30 | 17 | |||||||||
Depreciation, accretion and other amortization | (5) | 2 | |||||||||
Net gain on Enhanzed Re novation | — | (275) | |||||||||
Loss (income) from equity method investments | 5 | (11) | |||||||||
Other adjustments | (3) | (26) | |||||||||
Changes in: | |||||||||||
Reinsurance balances recoverable on paid and unpaid losses | 57 | (64) | |||||||||
Losses and loss adjustment expenses | (803) | (564) | |||||||||
Defendant asbestos and environmental liabilities | (11) | (11) | |||||||||
Insurance and reinsurance balances payable | 64 | 9 | |||||||||
Other operating assets and liabilities | 16 | (45) | |||||||||
Funds held | 367 | 290 | |||||||||
Cash from/to operating activities: | |||||||||||
Cash consideration for the Enhanzed Re novation | — | 94 | |||||||||
Sales and maturities of trading securities | 177 | 348 | |||||||||
Purchases of trading securities | (111) | (25) | |||||||||
Net cash flows (used in) provided by operating activities | (168) | 70 | |||||||||
INVESTING ACTIVITIES: | |||||||||||
Sales and maturities of available-for-sale securities | 529 | 736 | |||||||||
Purchase of available-for-sale securities | (345) | (589) | |||||||||
Purchase of other investments | (244) | (123) | |||||||||
Proceeds from other investments | 161 | 69 | |||||||||
Other investing activities | 1 | 1 | |||||||||
Net cash flows provided by investing activities | 102 | 94 | |||||||||
FINANCING ACTIVITIES: | |||||||||||
Dividends on preferred shares | (9) | (9) | |||||||||
Repurchase of shares | — | (340) | |||||||||
Other | 1 | — | |||||||||
Net cash flows used in financing activities | (8) | (349) | |||||||||
EFFECT OF EXCHANGE RATE CHANGES ON FOREIGN CURRENCY CASH AND CASH EQUIVALENTS | 4 | (2) | |||||||||
NET DECREASE IN CASH AND CASH EQUIVALENTS | (70) | (187) | |||||||||
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING OF PERIOD | 830 | 1,330 | |||||||||
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, END OF PERIOD | $ | 760 | $ | 1,143 | |||||||
Supplemental Cash Flow Information: | |||||||||||
Income taxes (received) paid, net of refunds | $ | (14) | $ | 1 | |||||||
Interest paid | $ | 32 | $ | 32 | |||||||
Reconciliation to Consolidated Balance Sheets: | |||||||||||
Cash and cash equivalents | $ | 450 | $ | 828 | |||||||
Restricted cash and cash equivalents | 310 | 315 | |||||||||
Cash, cash equivalents and restricted cash | $ | 760 | $ | 1,143 | |||||||
Non-cash operating activities: | |||||||||||
Novation of future policy holder benefits | — | 828 | |||||||||
Funds held directly managed transferred in exchange on novation of future policy holder benefits | — | (949) | |||||||||
Other assets / liabilities transferred on novation of future policy holder benefits | — | (62) | |||||||||
Losses and loss adjustment expenses transferred in connection with settlement of participation in Atrium's Syndicate 609 | — | 173 | |||||||||
Investments transferred in connection with settlement of participation in Atrium's Syndicate 609 | — | (173) | |||||||||
Non-cash investing activities: | |||||||||||
Unsettled purchases of available-for-sale securities and other investments | $ | 5 | $ | 14 | |||||||
Unsettled sales of available-for-sale securities and other investments | (10) | (8) | |||||||||
Three Months Ended | |||||||||||
March 31, | |||||||||||
2024 | 2023 | ||||||||||
(in millions of U.S. dollars) | |||||||||||
Revenues | |||||||||||
Run-off | $ | 14 | $ | 13 | |||||||
Investments | 239 | 344 | |||||||||
Assumed Life (1) | — | 275 | |||||||||
Subtotal | 253 | 632 | |||||||||
Corporate and other (1) | (3) | — | |||||||||
Total revenues | $ | 250 | $ | 632 | |||||||
(Loss) income from equity method investments | |||||||||||
Investments | $ | (5) | $ | 11 | |||||||
Segment net income (loss) | |||||||||||
Run-off | $ | (11) | $ | (5) | |||||||
Investments | 224 | 344 | |||||||||
Assumed Life (1) | — | 275 | |||||||||
Total segment net income | 213 | 614 | |||||||||
Corporate and other (1): | |||||||||||
Other expense (2) | (3) | — | |||||||||
Net incurred losses and loss adjustment expenses (“LAE”) (3) | 1 | (23) | |||||||||
Amortization of net deferred charge assets | (30) | (17) | |||||||||
General and administrative expenses | (35) | (39) | |||||||||
Interest expense | (22) | (23) | |||||||||
Net foreign exchange gains | 9 | 6 | |||||||||
Income tax (expense) benefit | (5) | 1 | |||||||||
Net income attributable to noncontrolling interests | — | (86) | |||||||||
Dividends on preferred shares | (9) | (9) | |||||||||
Total - Corporate and other loss | (94) | (190) | |||||||||
Net income attributable to Enstar Ordinary Shareholders | $ | 119 | $ | 424 |
March 31, 2024 | |||||||||||||||||||||||||||||
Short-term investments, trading | Short-term investments, AFS | Fixed maturities, trading | Fixed maturities, AFS | Total | |||||||||||||||||||||||||
(in millions of U.S. dollars) | |||||||||||||||||||||||||||||
U.S. government and agency | $ | — | $ | 20 | $ | 64 | $ | 207 | $ | 291 | |||||||||||||||||||
U.K. government | — | — | 18 | 42 | 60 | ||||||||||||||||||||||||
Other government | 2 | 2 | 115 | 245 | 364 | ||||||||||||||||||||||||
Corporate | 4 | 19 | 1,322 | 2,582 | 3,927 | ||||||||||||||||||||||||
Municipal | — | — | 46 | 86 | 132 | ||||||||||||||||||||||||
Residential mortgage-backed | — | — | 55 | 410 | 465 | ||||||||||||||||||||||||
Commercial mortgage-backed | — | — | 134 | 722 | 856 | ||||||||||||||||||||||||
Asset-backed | — | — | 108 | 752 | 860 | ||||||||||||||||||||||||
Total fixed maturity and short-term investments | $ | 6 | $ | 41 | $ | 1,862 | $ | 5,046 | $ | 6,955 |
December 31, 2023 | |||||||||||||||||||||||||||||
Short-term investments, trading | Short-term investments, AFS | Fixed maturities, trading | Fixed maturities, AFS | Total | |||||||||||||||||||||||||
(in millions of U.S. dollars) | |||||||||||||||||||||||||||||
U.S. government and agency | $ | — | $ | 38 | $ | 76 | $ | 212 | $ | 326 | |||||||||||||||||||
U.K. government | — | — | 21 | 51 | 72 | ||||||||||||||||||||||||
Other government | — | 2 | 144 | 245 | 391 | ||||||||||||||||||||||||
Corporate | 2 | 22 | 1,349 | 2,758 | 4,131 | ||||||||||||||||||||||||
Municipal | — | — | 49 | 93 | 142 | ||||||||||||||||||||||||
Residential mortgage-backed | — | — | 55 | 432 | 487 | ||||||||||||||||||||||||
Commercial mortgage-backed | — | — | 138 | 703 | 841 | ||||||||||||||||||||||||
Asset-backed | — | — | 117 | 767 | 884 | ||||||||||||||||||||||||
Total fixed maturity and short-term investments | $ | 2 | $ | 62 | $ | 1,949 | $ | 5,261 | $ | 7,274 |
As of March 31, 2024 | Amortized Cost | Fair Value | % of Total Fair Value | |||||||||||||||||
(in millions of U.S. dollars) | ||||||||||||||||||||
One year or less | $ | 350 | $ | 345 | 5.0 | % | ||||||||||||||
More than one year through five years | 2,202 | 2,085 | 29.9 | % | ||||||||||||||||
More than five years through ten years | 1,479 | 1,336 | 19.2 | % | ||||||||||||||||
More than ten years | 1,313 | 1,008 | 14.5 | % | ||||||||||||||||
Residential mortgage-backed | 507 | 465 | 6.7 | % | ||||||||||||||||
Commercial mortgage-backed | 916 | 856 | 12.3 | % | ||||||||||||||||
Asset-backed | 855 | 860 | 12.4 | % | ||||||||||||||||
$ | 7,622 | $ | 6,955 | 100.0 | % |
Gross Unrealized Gains | Gross Unrealized Losses | |||||||||||||||||||||||||||||||
As of March 31, 2024 | Amortized Cost | Non-Credit Related Losses | Allowance for Credit Losses | Fair Value | ||||||||||||||||||||||||||||
(in millions of U.S. dollars) | ||||||||||||||||||||||||||||||||
U.S. government and agency | $ | 246 | $ | — | $ | (19) | $ | — | $ | 227 | ||||||||||||||||||||||
U.K. government | 43 | 1 | (2) | — | 42 | |||||||||||||||||||||||||||
Other government | 257 | 1 | (11) | — | 247 | |||||||||||||||||||||||||||
Corporate | 2,891 | 10 | (284) | (16) | 2,601 | |||||||||||||||||||||||||||
Municipal | 101 | — | (15) | — | 86 | |||||||||||||||||||||||||||
Residential mortgage-backed | 449 | 2 | (41) | — | 410 | |||||||||||||||||||||||||||
Commercial mortgage-backed | 773 | 2 | (52) | (1) | 722 | |||||||||||||||||||||||||||
Asset-backed | 743 | 13 | (4) | — | 752 | |||||||||||||||||||||||||||
$ | 5,503 | $ | 29 | $ | (428) | $ | (17) | $ | 5,087 |
Gross Unrealized Gains | Gross Unrealized Losses | |||||||||||||||||||||||||||||||
As of December 31, 2023 | Amortized Cost | Non-Credit Related Losses | Allowance for Credit Losses | Fair Value | ||||||||||||||||||||||||||||
(in millions of U.S. dollars) | ||||||||||||||||||||||||||||||||
U.S. government and agency | $ | 268 | $ | 1 | $ | (19) | $ | — | $ | 250 | ||||||||||||||||||||||
U.K. government | 49 | 3 | (1) | — | 51 | |||||||||||||||||||||||||||
Other government | 250 | 5 | (8) | — | 247 | |||||||||||||||||||||||||||
Corporate | 3,040 | 23 | (268) | (15) | 2,780 | |||||||||||||||||||||||||||
Municipal | 107 | 1 | (15) | — | 93 | |||||||||||||||||||||||||||
Residential mortgage-backed | 466 | 3 | (37) | — | 432 | |||||||||||||||||||||||||||
Commercial mortgage-backed | 760 | 1 | (57) | (1) | 703 | |||||||||||||||||||||||||||
Asset-backed | 764 | 10 | (7) | — | 767 | |||||||||||||||||||||||||||
$ | 5,704 | $ | 47 | $ | (412) | $ | (16) | $ | 5,323 |
12 Months or Greater | Less Than 12 Months | Total | ||||||||||||||||||||||||||||||||||||
As of March 31, 2024 | Fair Value | Gross Unrealized Losses | Fair Value | Gross Unrealized Losses | Fair Value | Gross Unrealized Losses | ||||||||||||||||||||||||||||||||
(in millions of U.S. dollars) | ||||||||||||||||||||||||||||||||||||||
U.S. government and agency | $ | 122 | $ | (18) | $ | 74 | $ | (1) | $ | 196 | $ | (19) | ||||||||||||||||||||||||||
U.K. government | 9 | (2) | 5 | — | 14 | (2) | ||||||||||||||||||||||||||||||||
Other government | 61 | (8) | 137 | (3) | 198 | (11) | ||||||||||||||||||||||||||||||||
Corporate | 1,776 | (278) | 362 | (6) | 2,138 | (284) | ||||||||||||||||||||||||||||||||
Municipal | 76 | (15) | 3 | — | 79 | (15) | ||||||||||||||||||||||||||||||||
Residential mortgage-backed | 254 | (40) | 56 | (1) | 310 | (41) | ||||||||||||||||||||||||||||||||
Commercial mortgage-backed | 436 | (46) | 181 | (6) | 617 | (52) | ||||||||||||||||||||||||||||||||
Asset-backed | 92 | (3) | 172 | (1) | 264 | (4) | ||||||||||||||||||||||||||||||||
Total short-term and fixed maturity investments | $ | 2,826 | $ | (410) | $ | 990 | $ | (18) | $ | 3,816 | $ | (428) |
12 Months or Greater | Less Than 12 Months | Total | ||||||||||||||||||||||||||||||||||||
As of December 31, 2023 | Fair Value | Gross Unrealized Losses | Fair Value | Gross Unrealized Losses | Fair Value | Gross Unrealized Losses | ||||||||||||||||||||||||||||||||
(in millions of U.S. dollars) | ||||||||||||||||||||||||||||||||||||||
U.S. government and agency | $ | 135 | $ | (18) | $ | 43 | $ | (1) | $ | 178 | $ | (19) | ||||||||||||||||||||||||||
U.K. government | 9 | (1) | 4 | — | 13 | (1) | ||||||||||||||||||||||||||||||||
Other government | 70 | (8) | 10 | — | 80 | (8) | ||||||||||||||||||||||||||||||||
Corporate | 1,854 | (265) | 243 | (3) | 2,097 | (268) | ||||||||||||||||||||||||||||||||
Municipal | 78 | (15) | 2 | — | 80 | (15) | ||||||||||||||||||||||||||||||||
Residential mortgage-backed | 267 | (36) | 41 | (1) | 308 | (37) | ||||||||||||||||||||||||||||||||
Commercial mortgage-backed | 410 | (48) | 225 | (9) | 635 | (57) | ||||||||||||||||||||||||||||||||
Asset-backed | 239 | (6) | 100 | (1) | 339 | (7) | ||||||||||||||||||||||||||||||||
Total short-term and fixed maturity investments | $ | 3,062 | $ | (397) | $ | 668 | $ | (15) | $ | 3,730 | $ | (412) |
Three Months Ended March 31, | |||||||||||||||||||||||||||||||||||
2024 | 2023 | ||||||||||||||||||||||||||||||||||
Corporate | Commercial mortgage backed | Total | Other government | Corporate | Total | ||||||||||||||||||||||||||||||
(in millions of U.S. dollars) | |||||||||||||||||||||||||||||||||||
Allowance for credit losses, beginning of period | $ | (15) | $ | (1) | $ | (16) | $ | (1) | $ | (32) | $ | (33) | |||||||||||||||||||||||
Allowances for credit losses on securities for which credit losses were not previously recorded | — | — | — | — | (1) | (1) | |||||||||||||||||||||||||||||
Reductions for securities sold during the period | — | — | — | — | 3 | 3 | |||||||||||||||||||||||||||||
(Increase) decrease to the allowance for credit losses on securities that had an allowance recorded in the previous period | (1) | — | (1) | 1 | 9 | 10 | |||||||||||||||||||||||||||||
Allowance for credit losses, end of period | $ | (16) | $ | (1) | $ | (17) | $ | — | $ | (21) | $ | (21) |
March 31, 2024 | December 31, 2023 | ||||||||||
(in millions of U.S. dollars) | |||||||||||
Equity Investments | |||||||||||
Publicly traded equity investments in common and preferred stocks | $ | 310 | $ | 275 | |||||||
Exchange-traded funds | 84 | 82 | |||||||||
Privately held equity investments in common and preferred stocks | 344 | 344 | |||||||||
$ | 738 | $ | 701 | ||||||||
March 31, 2024 | December 31, 2023 | ||||||||||
(in millions of U.S. dollars) | |||||||||||
Other Investments | |||||||||||
Private equity funds | $ | 1,706 | $ | 1,617 | |||||||
Private credit funds | 642 | 625 | |||||||||
Hedge funds | 559 | 491 | |||||||||
Fixed income funds | 550 | 605 | |||||||||
Real estate funds | 336 | 269 | |||||||||
CLO equity funds | 161 | 182 | |||||||||
CLO equities | 60 | 60 | |||||||||
Equity funds | 4 | 4 | |||||||||
$ | 4,018 | $ | 3,853 | ||||||||
Less than 1 Year | 1-2 years | 2-3 years | More than 3 years | Not Eligible/ Restricted | Total | Redemption Frequency (1) | |||||||||||||||||||||||||||||||||||
(in millions of U.S. dollars) | |||||||||||||||||||||||||||||||||||||||||
Equities | |||||||||||||||||||||||||||||||||||||||||
Privately held equity investments | $ | — | $ | — | $ | — | $ | — | $ | 47 | $ | 47 | not eligible/ restricted | ||||||||||||||||||||||||||||
Other investments | |||||||||||||||||||||||||||||||||||||||||
Private equity funds | $ | 64 | $ | — | $ | — | $ | — | $ | 1,642 | $ | 1,706 | quarterly for unrestricted amount | ||||||||||||||||||||||||||||
Hedge funds | 559 | — | — | — | — | 559 | monthly to bi-annually | ||||||||||||||||||||||||||||||||||
Fixed income funds | 498 | — | — | — | 46 | 544 | monthly to quarterly | ||||||||||||||||||||||||||||||||||
Private credit funds | — | — | — | — | 459 | 459 | not eligible/ restricted | ||||||||||||||||||||||||||||||||||
Real estate funds | — | — | — | — | 336 | 336 | not eligible/ restricted | ||||||||||||||||||||||||||||||||||
CLO equity funds | 159 | — | — | — | 2 | 161 | quarterly to bi-annually | ||||||||||||||||||||||||||||||||||
$ | 1,280 | $ | — | $ | — | $ | — | $ | 2,532 | $ | 3,812 |
March 31, 2024 | December 31, 2023 | |||||||||||||||||||||||||
Ownership % | Carrying Value | Ownership % | Carrying Value | |||||||||||||||||||||||
(in millions of U.S. dollars) | ||||||||||||||||||||||||||
Monument Re (1) | 24.6 | % | 63 | 20.0 | % | 95 | ||||||||||||||||||||
Core Specialty | 19.9 | % | 251 | 19.9 | % | 225 | ||||||||||||||||||||
Other | 27.0 | % | 12 | 27.0% | 14 | |||||||||||||||||||||
$ | 326 | $ | 334 |
March 31, 2024 | December 31, 2023 | ||||||||||
(in millions of U.S. dollars) | |||||||||||
Funds held - directly managed | $ | 2,336 | $ | 2,502 | |||||||
Funds held by reinsured companies | 2,544 | 2,749 | |||||||||
Total funds held | $ | 4,880 | $ | 5,251 |
March 31, 2024 | December 31, 2023 | ||||||||||
(in millions of U.S. dollars) | |||||||||||
Funds held - directly managed, at cost | $ | 2,450 | $ | 2,608 | |||||||
Fair value changes in: | |||||||||||
Accumulated change in fair value - embedded derivative accounting | (114) | (106) | |||||||||
Funds held - directly managed, at fair value | $ | 2,336 | $ | 2,502 |
March 31, 2024 | December 31, 2023 | ||||||||||
(in millions of U.S. dollars) | |||||||||||
Funds held by reinsurance companies, at amortized cost | $ | 2,522 | $ | 2,709 | |||||||
Fair value of embedded derivative (1) | 22 | 40 | |||||||||
Funds held by reinsured companies | $ | 2,544 | $ | 2,749 |
Three Months Ended | |||||||||||
March 31, | |||||||||||
2024 | 2023 | ||||||||||
(in millions of U.S. dollars) | |||||||||||
Fixed maturity investments | $ | 84 | $ | 79 | |||||||
Short-term investments and cash and cash equivalents | 8 | 7 | |||||||||
Funds held | 58 | 50 | |||||||||
Investment income from fixed maturities and cash and cash equivalents | 150 | 136 | |||||||||
Equity investments | 8 | 14 | |||||||||
Other investments | 12 | 10 | |||||||||
Investment income from equities and other investments | 20 | 24 | |||||||||
Gross investment income | 170 | 160 | |||||||||
Investment expenses | (10) | (4) | |||||||||
Net investment income | $ | 160 | $ | 156 |
Three Months Ended | |||||||||||
March 31, | |||||||||||
2024 | 2023 | ||||||||||
(in millions of U.S. dollars) | |||||||||||
Net realized losses on sales: | |||||||||||
Gross realized gains on fixed maturity securities, AFS | $ | 5 | $ | 5 | |||||||
Gross realized losses on fixed maturity securities, AFS | (10) | (32) | |||||||||
(Increase) decrease in allowance for expected credit losses on fixed maturity securities, AFS | (1) | 9 | |||||||||
Total net realized losses on sales | $ | (6) | $ | (18) | |||||||
Fair value changes in trading securities, funds held and other investments: | |||||||||||
Fixed maturity securities, trading | $ | (14) | $ | 40 | |||||||
Funds held - directly managed | (5) | 19 | |||||||||
Equity securities | 37 | 53 | |||||||||
Other investments | 67 | 85 | |||||||||
Investment derivatives | — | 9 | |||||||||
Total fair value changes in trading securities, funds held and other investments | $ | 85 | $ | 206 | |||||||
Net realized gains and fair value changes in trading securities, funds held and other investments | $ | 79 | $ | 188 | |||||||
March 31, 2024 | December 31, 2023 | ||||||||||
(in millions of U.S. dollars) | |||||||||||
Collateral in trust for third party agreements | $ | 4,901 | $ | 5,301 | |||||||
Assets on deposit with regulatory authorities | 80 | 80 | |||||||||
Collateral for secured letter of credit facilities | 74 | 78 | |||||||||
Funds at Lloyd's (1) | 272 | 389 | |||||||||
$ | 5,327 | $ | 5,848 |
March 31, 2024 | December 31, 2023 | ||||||||||||||||||||||||||||||||||
Gross Notional Amount | Fair Value | Gross Notional Amount | Fair Value | ||||||||||||||||||||||||||||||||
Assets | Liabilities | Assets | Liabilities | ||||||||||||||||||||||||||||||||
(in millions of U.S. dollars) | |||||||||||||||||||||||||||||||||||
Derivatives designated as hedging instruments | |||||||||||||||||||||||||||||||||||
Foreign currency forward contracts | $ | 305 | $ | 2 | $ | — | $ | 424 | $ | 1 | $ | 6 | |||||||||||||||||||||||
Derivatives not designated as hedging instruments | |||||||||||||||||||||||||||||||||||
Foreign currency forward contracts | 368 | 2 | — | 313 | 3 | 3 | |||||||||||||||||||||||||||||
Others | 4 | — | — | 14 | — | — | |||||||||||||||||||||||||||||
Total | $ | 677 | $ | 4 | $ | — | $ | 751 | $ | 4 | $ | 9 |
Three Months Ended March 31, | |||||||||||
2024 | 2023 | ||||||||||
(in millions of U.S. dollars) | |||||||||||
Beginning carrying value | $ | 731 | $ | 658 | |||||||
Amortization | (30) | (17) | |||||||||
Ending carrying value | $ | 701 | $ | 641 |
Three Months Ended | |||||||||||
March 31, | |||||||||||
2024 | 2023 | ||||||||||
(in millions of U.S. dollars) | |||||||||||
Balance as of beginning of period | $ | 12,359 | $ | 13,007 | |||||||
Reinsurance reserves recoverable on unpaid losses | (774) | (996) | |||||||||
Net balance as of beginning of period | 11,585 | 12,011 | |||||||||
Net incurred losses and LAE: | |||||||||||
Current period: | |||||||||||
Increase in estimates of net ultimate losses | 5 | 10 | |||||||||
Total current period | 5 | 10 | |||||||||
Prior periods: | |||||||||||
Reduction in estimates of net ultimate losses | (6) | (15) | |||||||||
Reduction in provisions for ULAE | (17) | (18) | |||||||||
Amortization of fair value adjustments | 3 | 3 | |||||||||
Changes in fair value - fair value option (1) | (4) | 20 | |||||||||
Total prior periods | (24) | (10) | |||||||||
Total net incurred losses and LAE | (19) | — | |||||||||
Net paid losses: | |||||||||||
Current period | — | (1) | |||||||||
Prior periods | (670) | (676) | |||||||||
Total net paid losses | (670) | (677) | |||||||||
Other changes: | |||||||||||
Effect of exchange rate movement | (69) | 31 | |||||||||
Ceded business (2) | — | (139) | |||||||||
Total other changes | (69) | (108) | |||||||||
Net balance as of March 31 | 10,827 | 11,226 | |||||||||
Reinsurance reserves recoverable on unpaid losses | 723 | 960 | |||||||||
Balance as of March 31 | $ | 11,550 | $ | 12,186 | |||||||
As of | |||||||||||
March 31, 2024 | December 31, 2023 | ||||||||||
(in millions of U.S. dollars) | |||||||||||
Reconciliation to Consolidated Balance Sheets: | |||||||||||
Losses and loss adjustment expenses | $ | 10,452 | $ | 11,196 | |||||||
Losses and loss adjustment expenses, at fair value | 1,098 | 1,163 | |||||||||
Total losses and loss adjustment expenses | $ | 11,550 | $ | 12,359 | |||||||
Reinsurance balances recoverable on paid and unpaid losses | $ | 692 | $ | 740 | |||||||
Reinsurance balances recoverable on paid and unpaid losses - fair value option | 207 | 217 | |||||||||
Total reinsurance balances recoverable on paid and unpaid losses | 899 | 957 | |||||||||
Less: Paid losses recoverable | (176) | (183) | |||||||||
Reinsurance reserves recoverable on unpaid losses | $ | 723 | $ | 774 |
Three Months Ended | |||||||||||
March 31, 2024 | March 31, 2023 | ||||||||||
(in millions of U.S. dollars) | |||||||||||
Asbestos | $ | (24) | $ | — | |||||||
Environmental | 25 | — | |||||||||
General casualty | 18 | 4 | |||||||||
Workers' compensation | (2) | (11) | |||||||||
Marine, aviation and transit | — | (4) | |||||||||
Construction defect | 2 | — | |||||||||
Professional indemnity/Directors and Officers | (29) | 1 | |||||||||
Motor | 4 | — | |||||||||
Property | (1) | (3) | |||||||||
All Other | 1 | (2) | |||||||||
Total | $ | (6) | $ | (15) | |||||||
Three Months Ended March 31, | ||||||||
2023 | ||||||||
(in millions of U.S. dollars) | ||||||||
Beginning Balance | $ | 821 | ||||||
Benefits paid | (6) | |||||||
Effect of exchange rate movement | 13 | |||||||
Derecognition (1) | (828) | |||||||
Balance as of March 31 | — |
(in millions of U.S. dollars) | ||||||||
Calculation of carrying value as of transaction closing: | ||||||||
Funds held - directly managed and other assumed reinsurance recoverables | $ | 973 | ||||||
Future policyholder benefits (corresponds to derecognition referenced above) | (828) | |||||||
Other assumed reinsurance liabilities | (12) | |||||||
Carrying value of net assets | $ | 133 | ||||||
Calculation of gain on novation (recorded in first quarter 2023): | ||||||||
Cash consideration received | $ | 94 | ||||||
Less: carrying value of net assets | (133) | |||||||
Add: reclassification of remeasurement of future policyholder benefits from AOCI and NCI (1) | 363 | |||||||
Amount deferred relating to 20% ownership interest in Monument Re (2) | (49) | |||||||
Gain on novation (3) | 275 | |||||||
Net income attributable to noncontrolling interest | (81) | |||||||
Gain on novation attributable to Enstar (4) | $ | 194 |
March 31, 2024 | December 31, 2023 | ||||||||||
(in millions of U.S. dollars) | |||||||||||
Defendant A&E liabilities: | |||||||||||
Defendant asbestos liabilities | $ | 720 | $ | 734 | |||||||
Defendant environmental liabilities | 10 | 10 | |||||||||
Estimated future expenses | 32 | 33 | |||||||||
Fair value adjustments | (206) | (210) | |||||||||
Defendant A&E liabilities | 556 | 567 | |||||||||
Insurance balances recoverable: | |||||||||||
Insurance recoverables related to defendant asbestos liabilities (net of allowance: 2024 and 2023 - $5) | 214 | 217 | |||||||||
Fair value adjustments | (44) | (45) | |||||||||
Insurance balances recoverable | 170 | 172 | |||||||||
Net liabilities relating to defendant A&E exposures | $ | 386 | $ | 395 |
Three Months Ended | |||||||||||
March 31, | |||||||||||
2024 | 2023 | ||||||||||
(in millions of U.S. dollars) | |||||||||||
Balance as of beginning of period | $ | 567 | $ | 607 | |||||||
Insurance balances recoverable | (172) | (177) | |||||||||
Net balance as of beginning of period | 395 | 430 | |||||||||
Total paid claims | (12) | (11) | |||||||||
Amounts recorded in other expense (income): | |||||||||||
Reduction in estimates of ultimate net liabilities | — | (2) | |||||||||
Reduction in estimated future expenses | (1) | (1) | |||||||||
Amortization of fair value adjustments | 4 | 4 | |||||||||
Total other expense | 3 | 1 | |||||||||
Net balance as of March 31 | 386 | 420 | |||||||||
Insurance balances recoverable | 170 | 176 | |||||||||
Balance as of March 31 | $ | 556 | $ | 596 |
March 31, 2024 | |||||||||||||||||||||||||||||
Quoted Prices in Active Markets for Identical Assets (Level 1) | Significant Other Observable Inputs (Level 2) | Significant Unobservable Inputs (Level 3) | Measured Using NAV as Practical Expedient | Total Fair Value | |||||||||||||||||||||||||
(in millions of U.S. dollars) | |||||||||||||||||||||||||||||
Investments: | |||||||||||||||||||||||||||||
Short-term and fixed maturity investments: | |||||||||||||||||||||||||||||
U.S. government and agency | $ | — | $ | 291 | $ | — | $ | — | $ | 291 | |||||||||||||||||||
U.K. government | — | 60 | — | — | 60 | ||||||||||||||||||||||||
Other government | — | 364 | — | — | 364 | ||||||||||||||||||||||||
Corporate | — | 3,910 | 17 | — | 3,927 | ||||||||||||||||||||||||
Municipal | — | 132 | — | — | 132 | ||||||||||||||||||||||||
Residential mortgage-backed | — | 465 | — | — | 465 | ||||||||||||||||||||||||
Commercial mortgage-backed | — | 856 | — | — | 856 | ||||||||||||||||||||||||
Asset-backed | — | 834 | 26 | — | 860 | ||||||||||||||||||||||||
$ | — | $ | 6,912 | $ | 43 | $ | — | $ | 6,955 | ||||||||||||||||||||
Funds held (1) | $ | 55 | $ | 2,178 | $ | 22 | $ | 103 | $ | 2,358 | |||||||||||||||||||
Equities: | |||||||||||||||||||||||||||||
Publicly traded equity investments | $ | 275 | $ | 34 | $ | 1 | $ | — | $ | 310 | |||||||||||||||||||
Exchange-traded funds | 84 | — | — | — | 84 | ||||||||||||||||||||||||
Privately held equity investments | — | — | 297 | 47 | 344 | ||||||||||||||||||||||||
$ | 359 | $ | 34 | $ | 298 | $ | 47 | $ | 738 | ||||||||||||||||||||
Other investments: | |||||||||||||||||||||||||||||
Private equity funds | — | — | — | 1,706 | 1,706 | ||||||||||||||||||||||||
Private credit funds | — | 183 | — | 459 | 642 | ||||||||||||||||||||||||
Hedge funds | $ | — | $ | — | $ | — | $ | 559 | $ | 559 | |||||||||||||||||||
Fixed income funds | — | 6 | — | 544 | 550 | ||||||||||||||||||||||||
Real estate debt fund | — | — | — | 336 | 336 | ||||||||||||||||||||||||
CLO equity funds | — | — | — | 161 | 161 | ||||||||||||||||||||||||
CLO equities | — | 60 | — | — | 60 | ||||||||||||||||||||||||
Equity funds | — | 4 | — | — | 4 | ||||||||||||||||||||||||
$ | — | $ | 253 | $ | — | $ | 3,765 | $ | 4,018 | ||||||||||||||||||||
Total Investments | $ | 414 | $ | 9,377 | $ | 363 | $ | 3,915 | $ | 14,069 | |||||||||||||||||||
Reinsurance balances recoverable on paid and unpaid losses: | $ | — | $ | — | $ | 207 | $ | — | $ | 207 | |||||||||||||||||||
Other Assets: | |||||||||||||||||||||||||||||
Derivatives qualifying as hedging | $ | — | $ | 2 | $ | — | $ | — | $ | 2 | |||||||||||||||||||
Derivatives not qualifying as hedging | — | 2 | — | — | 2 | ||||||||||||||||||||||||
Derivative instruments | $ | — | $ | 4 | $ | — | $ | — | $ | 4 | |||||||||||||||||||
Losses and LAE: | $ | — | $ | — | $ | 1,098 | $ | — | $ | 1,098 | |||||||||||||||||||
December 31, 2023 | ||||||||||||||||||||||||||||||||
Quoted Prices in Active Markets for Identical Assets (Level 1) | Significant Other Observable Inputs (Level 2) | Significant Unobservable Inputs (Level 3) | Measured Using NAV as Practical Expedient | Total Fair Value | ||||||||||||||||||||||||||||
(in millions of U.S. dollars) | ||||||||||||||||||||||||||||||||
Investments: | ||||||||||||||||||||||||||||||||
Short-term and fixed maturity investments: | ||||||||||||||||||||||||||||||||
U.S. government and agency | $ | — | $ | 326 | $ | — | $ | — | $ | 326 | ||||||||||||||||||||||
U.K government | — | 72 | — | — | 72 | |||||||||||||||||||||||||||
Other government | — | 391 | — | — | 391 | |||||||||||||||||||||||||||
Corporate | — | 4,119 | 12 | — | 4,131 | |||||||||||||||||||||||||||
Municipal | — | 142 | — | — | 142 | |||||||||||||||||||||||||||
Residential mortgage-backed | — | 487 | — | — | 487 | |||||||||||||||||||||||||||
Commercial mortgage-backed | — | 841 | — | — | 841 | |||||||||||||||||||||||||||
Asset-backed | — | 873 | 11 | — | 884 | |||||||||||||||||||||||||||
— | 7,251 | 23 | — | 7,274 | ||||||||||||||||||||||||||||
Funds held (1) | $ | 58 | $ | 2,342 | $ | 40 | $ | 102 | $ | 2,542 | ||||||||||||||||||||||
Equities: | ||||||||||||||||||||||||||||||||
Publicly traded equity investments | $ | 243 | $ | 31 | $ | 1 | $ | — | $ | 275 | ||||||||||||||||||||||
Exchange-traded funds | 82 | — | — | — | 82 | |||||||||||||||||||||||||||
Privately held equity investments | — | — | 299 | 45 | 344 | |||||||||||||||||||||||||||
$ | 325 | $ | 31 | $ | 300 | $ | 45 | $ | 701 | |||||||||||||||||||||||
Other investments: | ||||||||||||||||||||||||||||||||
Private equity funds | $ | — | $ | — | $ | — | $ | 1,617 | $ | 1,617 | ||||||||||||||||||||||
Private credit funds | — | 183 | — | 442 | 625 | |||||||||||||||||||||||||||
Fixed income funds | — | 53 | — | 552 | 605 | |||||||||||||||||||||||||||
Hedge funds | — | — | — | 491 | 491 | |||||||||||||||||||||||||||
Real estate debt fund | — | — | — | 269 | 269 | |||||||||||||||||||||||||||
CLO equity funds | — | — | — | 182 | 182 | |||||||||||||||||||||||||||
CLO equities | — | 60 | — | — | 60 | |||||||||||||||||||||||||||
Equity funds | — | 4 | — | — | 4 | |||||||||||||||||||||||||||
$ | — | $ | 300 | $ | — | $ | 3,553 | $ | 3,853 | |||||||||||||||||||||||
Total Investments | $ | 383 | $ | 9,924 | $ | 363 | $ | 3,700 | $ | 14,370 | ||||||||||||||||||||||
Reinsurance balances recoverable on paid and unpaid losses: | $ | — | $ | — | $ | 217 | $ | — | $ | 217 | ||||||||||||||||||||||
Other Assets: | ||||||||||||||||||||||||||||||||
Derivatives qualifying as hedging | $ | — | $ | 1 | $ | — | $ | — | $ | 1 | ||||||||||||||||||||||
Derivatives not qualifying as hedging | — | 3 | — | — | 3 | |||||||||||||||||||||||||||
Derivative instruments | $ | — | $ | 4 | $ | — | $ | — | $ | 4 | ||||||||||||||||||||||
Losses and LAE: | $ | — | $ | — | $ | 1,163 | $ | — | $ | 1,163 | ||||||||||||||||||||||
Other Liabilities: | ||||||||||||||||||||||||||||||||
Derivatives qualifying as hedging | $ | — | $ | 6 | $ | — | $ | — | $ | 6 | ||||||||||||||||||||||
Derivatives not qualifying as hedging | — | 3 | — | — | 3 | |||||||||||||||||||||||||||
Derivative instruments | $ | — | $ | 9 | $ | — | $ | — | $ | 9 |
Three Months Ended | |||||||||||||||||||||||||||||||||||||||||
March 31, 2024 | March 31, 2023 | ||||||||||||||||||||||||||||||||||||||||
Fixed maturity investments | Equities | Total | Equities | Total | |||||||||||||||||||||||||||||||||||||
Corporate | Asset-backed | Privately-held Equities | Public Equities | Privately-held Equities | |||||||||||||||||||||||||||||||||||||
(in millions of U.S. dollars) | |||||||||||||||||||||||||||||||||||||||||
Beginning fair value | $ | 12 | $ | 11 | $ | 299 | $ | 1 | $ | 323 | $ | 294 | $ | 294 | |||||||||||||||||||||||||||
Total fair value changes in trading securities, funds held and other investments (1) | — | — | (2) | — | (2) | (2) | (2) | ||||||||||||||||||||||||||||||||||
Transfer into Level 3 from Level 2 | 5 | 15 | — | — | 20 | — | — | ||||||||||||||||||||||||||||||||||
Ending fair value | $ | 17 | $ | 26 | $ | 297 | $ | 1 | $ | 341 | $ | 292 | $ | 292 |
Qualitative Information about Level 3 Fair Value Measurements | ||||||||||||||||||||
Valuation Techniques | Fair Value as of March 31, 2024 | Unobservable Input | Range (Average) (1) | |||||||||||||||||
(in millions of U.S. dollars) | ||||||||||||||||||||
Fixed maturities | ||||||||||||||||||||
Corporate | YTM | |||||||||||||||||||
Discounted cash flow | $ | 17 | 6.45% - 10.92% | |||||||||||||||||
Asset-backed | ||||||||||||||||||||
Discounted cash flow | 16 | 7.59% - 7.86% | ||||||||||||||||||
Cost | 10 | |||||||||||||||||||
26 | ||||||||||||||||||||
Total fixed maturities | $ | 43 | ||||||||||||||||||
Privately held equity investments | ||||||||||||||||||||
Guideline company methodology; Option pricing model | $ | 179 | P/BV multiple P/BV (excluding AOCI) multiple Expected term | 1.50x - 1.9x 1.4x -1.5x 1-3 years | ||||||||||||||||
Guideline companies method | 54 | P/BV multiple Price/2024 earnings | 1.5x - 1.7x 7.7x - 8.9x | |||||||||||||||||
Guideline companies method; Earnings | 30 | LTM Enterprise Value/ EBITDA multiples LTM EV/Revenue multiples Multiple on earnings | 12x - 13x 2.5x - 3x 5x | |||||||||||||||||
Dividend discount model | 34 | Discount rate | 8.5% | |||||||||||||||||
297 | ||||||||||||||||||||
Publicly traded equity investments | ||||||||||||||||||||
Discounted cash flow | 1 | Implied total yield | 8.62% | |||||||||||||||||
Total equity investments | $ | 298 |
Three Months Ended March 31, | |||||||||||
2024 | 2023 | ||||||||||
(in millions of U.S. dollars) | |||||||||||
Beginning fair value | $ | 40 | $ | 44 | |||||||
Total fair value changes | (18) | 10 | |||||||||
Ending fair value | $ | 22 | $ | 54 |
Qualitative Information about Level 3 Fair Value Measurements | ||||||||||||||||||||
Valuation Techniques | Fair Value as of March 31, 2024 | Unobservable Input | Average | |||||||||||||||||
(in millions of U.S. dollars) | ||||||||||||||||||||
Monte Carlo simulation model; Discounted cash flow analysis | $ | 22 | Volatility rate; Expected Loss Payments | 6.37% $530 million | ||||||||||||||||
Three Months Ended March 31, | |||||||||||||||||||||||||||||||||||
2024 | 2023 | ||||||||||||||||||||||||||||||||||
Liability for losses and LAE | Reinsurance balances recoverable | Net | Liability for losses and LAE | Reinsurance balances recoverable | Net | ||||||||||||||||||||||||||||||
(in millions of U.S. dollars) | |||||||||||||||||||||||||||||||||||
Beginning fair value | $ | 1,163 | $ | 217 | $ | 946 | $ | 1,286 | $ | 275 | $ | 1,011 | |||||||||||||||||||||||
Incurred losses and LAE: | |||||||||||||||||||||||||||||||||||
Increase (reduction) in estimates of ultimate losses | (6) | (9) | 3 | 6 | 1 | 5 | |||||||||||||||||||||||||||||
Reduction in provisions for ULAE | (2) | — | (2) | (3) | — | (3) | |||||||||||||||||||||||||||||
Changes in fair value due to changes in: | |||||||||||||||||||||||||||||||||||
Average payout | 10 | 2 | 8 | 14 | 2 | 12 | |||||||||||||||||||||||||||||
Corporate bond yield | (16) | (3) | (13) | 11 | 3 | 8 | |||||||||||||||||||||||||||||
Risk cost of capital | 1 | — | 1 | — | — | — | |||||||||||||||||||||||||||||
Total change in fair value | (5) | (1) | (4) | 25 | 5 | 20 | |||||||||||||||||||||||||||||
Total incurred losses and LAE | (13) | (10) | (3) | 28 | 6 | 22 | |||||||||||||||||||||||||||||
Paid losses | (39) | (6) | (33) | (78) | (17) | (61) | |||||||||||||||||||||||||||||
Effect of exchange rate movements | (13) | 6 | (19) | 14 | 1 | 13 | |||||||||||||||||||||||||||||
Ending fair value | $ | 1,098 | $ | 207 | $ | 891 | $ | 1,250 | $ | 265 | $ | 985 |
Valuation Technique | March 31, 2024 | December 31, 2023 | ||||||||||||
Unobservable (U) and Observable (O) Inputs | Weighted Average | |||||||||||||
Internal model | Corporate bond yield (O) | A Rated | A Rated | |||||||||||
Internal model | Credit spread for Instrument-specific credit risk (U) | 0.65% | 0.65% | |||||||||||
Internal model | Risk cost of capital (U) | 5.65% | 5.60% | |||||||||||
Internal model | Weighted average cost of capital (U) | 8.75% | 8.75% | |||||||||||
Internal model | Average payout - liability (U) | 8.13 years | 8.12 years | |||||||||||
Internal model | Average payout - reinsurance balances recoverable on paid and unpaid losses (U) | 8.53 years | 8.35 years |
March 31, 2024 | ||||||||||||||
Amortized Cost | Fair Value | |||||||||||||
(in millions of U.S. dollars) | ||||||||||||||
4.95% Senior Notes due 2029 | $ | 496 | $ | 489 | ||||||||||
3.10% Senior Notes due 2031 | 496 | 413 | ||||||||||||
Total Senior Notes | $ | 992 | $ | 902 | ||||||||||
5.75% Junior Subordinated Notes due 2040 | $ | 346 | $ | 341 | ||||||||||
5.50% Junior Subordinated Notes due 2042 | 494 | 467 | ||||||||||||
Total Junior Subordinated Notes | $ | 840 | $ | 808 |
March 31, 2024 | December 31, 2023 | ||||||||||||||||||||||||||||||||||
Fair Value | Unfunded Commitments | Maximum Exposure to Loss | Fair Value | Unfunded Commitments | Maximum Exposure to Loss | ||||||||||||||||||||||||||||||
(in millions of U.S. dollars) | |||||||||||||||||||||||||||||||||||
Equities | |||||||||||||||||||||||||||||||||||
Publicly traded equity investment in common stock | $ | 72 | $ | — | $ | 72 | $ | 55 | $ | — | $ | 55 | |||||||||||||||||||||||
Privately Held Equity | 25 | — | 25 | 34 | — | 34 | |||||||||||||||||||||||||||||
Total | $ | 97 | $ | — | $ | 97 | $ | 89 | $ | — | $ | 89 | |||||||||||||||||||||||
Other investments | |||||||||||||||||||||||||||||||||||
Hedge funds | $ | 559 | $ | — | $ | 559 | $ | 491 | $ | — | $ | 491 | |||||||||||||||||||||||
Fixed income funds | 140 | 35 | 175 | 147 | 35 | 182 | |||||||||||||||||||||||||||||
Private equity funds | 1,298 | 631 | 1,929 | 1,262 | 667 | 1,929 | |||||||||||||||||||||||||||||
CLO equity funds | 160 | — | 160 | 182 | — | 182 | |||||||||||||||||||||||||||||
Private credit funds | 367 | 236 | 603 | 349 | 242 | 591 | |||||||||||||||||||||||||||||
Real estate funds | 135 | 172 | 307 | 121 | 139 | 260 | |||||||||||||||||||||||||||||
Total | $ | 2,659 | $ | 1,074 | $ | 3,733 | $ | 2,552 | $ | 1,083 | $ | 3,635 | |||||||||||||||||||||||
Total investments in nonconsolidated VIEs | $ | 2,756 | $ | 1,074 | $ | 3,830 | $ | 2,641 | $ | 1,083 | $ | 3,724 |
Three Months Ended | |||||
March 31, | |||||
2023 | |||||
(in millions of U.S. dollars) | |||||
Balance at beginning of period | $ | 168 | |||
Net income attributable to RNCI | 1 | ||||
Change in unrealized gains on AFS investments attributable to RNCI | 1 | ||||
Balance as of March 31 | $ | 170 |
Total Voting Ordinary Shares | |||||
Balance as of December 31, 2023 | 15,196,685 | ||||
Shares issued (1) | 27,746 | ||||
Balance as of March 31, 2024 | 15,224,431 | ||||
Three Months Ended | |||||||||||||||||||||||
March 31, | |||||||||||||||||||||||
2024 | |||||||||||||||||||||||
Unrealized gains (losses) arising during the year | Cumulative Currency Translation Adjustment | Insurance contracts - net liability for losses and LAE at fair value - Instrument-specific credit risk | Total | ||||||||||||||||||||
(in millions of U.S. dollars) | |||||||||||||||||||||||
Balance December 31, 2023, net of tax | $ | (368) | $ | 12 | $ | 20 | $ | (336) | |||||||||||||||
Unrealized losses on fixed maturities, AFS arising during the period | (33) | — | — | (33) | |||||||||||||||||||
Reclassification adjustment for change in allowance for credit losses recognized in net income | 1 | — | — | 1 | |||||||||||||||||||
Reclassification adjustment for net realized losses included in net income | 5 | — | — | 5 | |||||||||||||||||||
Change in currency translation adjustment | — | (1) | — | (1) | |||||||||||||||||||
Other comprehensive loss | (27) | (1) | — | (28) | |||||||||||||||||||
Balance March 31, 2024, net of tax | $ | (395) | $ | 11 | $ | 20 | $ | (364) |
Three Months Ended | |||||||||||||||||||||||
March 31, | |||||||||||||||||||||||
2023 | |||||||||||||||||||||||
Unrealized gains (losses) on available-for-sale investments | Cumulative currency translation adjustment | Remeasurement of future policyholder benefits - change in discount rate | Total | ||||||||||||||||||||
(in millions of U.S. dollars) | |||||||||||||||||||||||
Balance December 31, 2022, net of tax | $ | (584) | $ | 9 | $ | 273 | $ | (302) | |||||||||||||||
Unrealized gains on fixed maturities, AFS arising during the period | 57 | — | — | 57 | |||||||||||||||||||
Reclassification adjustment for change in allowance for credit losses recognized in net income | (9) | — | — | (9) | |||||||||||||||||||
Reclassification adjustment for net realized losses included in net income | 27 | — | — | 27 | |||||||||||||||||||
Change in currency translation adjustment | — | 5 | — | 5 | |||||||||||||||||||
Reclassification adjustment for remeasurement of future policyholder benefits included in net income | — | — | (363) | (363) | |||||||||||||||||||
Other comprehensive income (loss) | 75 | 5 | (363) | (283) | |||||||||||||||||||
Other comprehensive (income) loss attributable to NCI and RNCI | (1) | — | 90 | 89 | |||||||||||||||||||
Balance March 31, 2023, net of tax | $ | (510) | $ | 14 | $ | — | $ | (496) |
Three Months Ended | |||||||||||||||||||||||||||||||||||
March 31, | |||||||||||||||||||||||||||||||||||
2024 | 2023 | ||||||||||||||||||||||||||||||||||
Before Tax Amount | Tax (Expense) Benefit | Net of Tax Amount | Before Tax Amount | Tax (Expense) Benefit | Net of Tax Amount | ||||||||||||||||||||||||||||||
(in millions of U.S. dollars) | |||||||||||||||||||||||||||||||||||
Unrealized (losses) gains on fixed maturities, AFS arising during the period | $ | (41) | $ | 8 | $ | (33) | $ | 58 | $ | (1) | $ | 57 | |||||||||||||||||||||||
Reclassification adjustment for change in allowance for credit losses recognized in net income | 1 | — | 1 | (9) | — | (9) | |||||||||||||||||||||||||||||
Reclassification adjustment for net realized losses included in net income | 5 | — | 5 | 27 | — | 27 | |||||||||||||||||||||||||||||
Change in currency translation adjustment | (1) | — | (1) | 5 | — | 5 | |||||||||||||||||||||||||||||
Remeasurement of future policyholder benefits - change in interest rate | — | — | — | (363) | — | (363) | |||||||||||||||||||||||||||||
Other comprehensive loss | $ | (36) | $ | 8 | $ | (28) | $ | (282) | $ | (1) | $ | (283) |
Three Months Ended | ||||||||||||||
March 31, | ||||||||||||||
Details about AOCI components | 2024 | 2023 | Affected Line Item in Statement where Net Income are presented | |||||||||||
(in millions of U.S. dollars) | ||||||||||||||
Unrealized losses on fixed maturities, AFS | $ | (6) | $ | (18) | Net realized losses | |||||||||
(6) | (18) | Net of tax | ||||||||||||
Remeasurement of future policyholder benefits | — | 363 | Other income | |||||||||||
Total reclassifications for the period, net of tax | $ | (6) | $ | 345 | ||||||||||
Three Months Ended | |||||||||||
March 31, | |||||||||||
2024 | 2023 | ||||||||||
(in millions of U.S. dollars) | |||||||||||
Net income attributable to Enstar ordinary shareholders | $ | 119 | $ | 424 | |||||||
Transfers from noncontrolling interests: | |||||||||||
Increase in Enstar’s additional paid-in capital for purchase of noncontrolling interest (1) | — | 9 | |||||||||
Change from net income attributable to Enstar ordinary shareholders and net transfers from noncontrolling interests | $ | 119 | $ | 433 |
Three Months Ended | |||||||||||
March 31, | |||||||||||
2024 | 2023 | ||||||||||
(in millions of U.S. dollars, except share and per share data) | |||||||||||
Numerator: | |||||||||||
Net income attributable to Enstar ordinary shareholders: | $ | 119 | $ | 424 | |||||||
Denominator: | |||||||||||
Weighted-average ordinary shares outstanding — basic (1) | 14,641,158 | 16,980,240 | |||||||||
Effect of dilutive securities: | |||||||||||
Share-based compensation plans (2) | 192,682 | 120,714 | |||||||||
Weighted-average ordinary shares outstanding — diluted | 14,833,840 | 17,100,954 | |||||||||
Earnings per share attributable to Enstar ordinary shareholders: | |||||||||||
Basic | $ | 8.13 | $ | 24.97 | |||||||
Diluted | $ | 8.02 | $ | 24.79 | |||||||
As of March 31, 2024 | Stone Point (1) (2) | Monument | AmTrust | Citco | Core Specialty | Other (3) | |||||||||||||||||||||||||||||
(in millions of U.S. dollars) | |||||||||||||||||||||||||||||||||||
Assets | |||||||||||||||||||||||||||||||||||
Fixed maturities, trading, at fair value | $ | 69 | $ | — | $ | — | $ | — | $ | — | $ | — | |||||||||||||||||||||||
Fixed maturities, AFS, at fair value | 354 | — | — | — | — | — | |||||||||||||||||||||||||||||
Equities, at fair value | 146 | — | 179 | — | — | — | |||||||||||||||||||||||||||||
Funds held | — | — | — | — | 14 | — | |||||||||||||||||||||||||||||
Other investments, at fair value | 396 | — | — | — | — | 1,620 | |||||||||||||||||||||||||||||
Equity method investments | — | 63 | — | — | 251 | 12 | |||||||||||||||||||||||||||||
Total investments | 965 | 63 | 179 | — | 265 | 1,632 | |||||||||||||||||||||||||||||
Cash and cash equivalents | 9 | — | — | — | — | — | |||||||||||||||||||||||||||||
Other assets | — | — | — | 21 | 6 | — | |||||||||||||||||||||||||||||
Liabilities | |||||||||||||||||||||||||||||||||||
Losses and LAE | — | — | — | — | 179 | — | |||||||||||||||||||||||||||||
Insurance and reinsurance balances payable | — | — | — | — | 1 | — | |||||||||||||||||||||||||||||
Other liabilities | 2 | — | — | — | — | — | |||||||||||||||||||||||||||||
Net assets | $ | 972 | $ | 63 | $ | 179 | $ | 21 | $ | 91 | $ | 1,632 | |||||||||||||||||||||||
As of December 31, 2023 | Stone Point | Monument | AmTrust | Citco | Core Specialty | Other | |||||||||||||||||||||||||||||
(in millions of U.S. dollars) | |||||||||||||||||||||||||||||||||||
Assets | |||||||||||||||||||||||||||||||||||
Fixed maturities, trading, at fair value | $ | 69 | $ | — | $ | — | $ | — | $ | — | $ | — | |||||||||||||||||||||||
Fixed maturities, AFS, at fair value | 428 | — | — | — | — | — | |||||||||||||||||||||||||||||
Equities, at fair value | 136 | — | 181 | — | — | — | |||||||||||||||||||||||||||||
Funds held | — | — | — | — | 19 | — | |||||||||||||||||||||||||||||
Other investments, at fair value | 446 | — | — | — | — | 1,602 | |||||||||||||||||||||||||||||
Equity method investments | — | 95 | — | — | 225 | 14 | |||||||||||||||||||||||||||||
Total investments | 1,079 | 95 | 181 | — | 244 | 1,616 | |||||||||||||||||||||||||||||
Cash and cash equivalents | 19 | — | — | — | — | — | |||||||||||||||||||||||||||||
Other assets | — | — | — | 20 | 9 | — | |||||||||||||||||||||||||||||
Liabilities | |||||||||||||||||||||||||||||||||||
Losses and LAE | — | — | — | — | 192 | — | |||||||||||||||||||||||||||||
Net assets | $ | 1,098 | $ | 95 | $ | 181 | $ | 20 | $ | 61 | $ | 1,616 | |||||||||||||||||||||||
Three Months Ended | |||||||||||||||||||||||||||||||||||
March 31, 2024 | |||||||||||||||||||||||||||||||||||
Stone Point | Monument | AmTrust | Citco | Core Specialty | Other | ||||||||||||||||||||||||||||||
(in millions of U.S. dollars) | |||||||||||||||||||||||||||||||||||
REVENUES | |||||||||||||||||||||||||||||||||||
Net premiums earned | $ | — | $ | — | $ | — | $ | — | $ | — | $ | — | |||||||||||||||||||||||
Net investment income | 2 | — | 2 | — | — | 3 | |||||||||||||||||||||||||||||
Fair value changes in trading securities, funds held and other investments | 26 | — | (2) | — | — | 12 | |||||||||||||||||||||||||||||
Total revenues | 28 | — | — | — | — | 15 | |||||||||||||||||||||||||||||
EXPENSES | |||||||||||||||||||||||||||||||||||
Net incurred losses and LAE | — | — | — | — | 23 | — | |||||||||||||||||||||||||||||
Total expenses | — | — | — | — | 23 | — | |||||||||||||||||||||||||||||
(Loss) income from equity method investments | — | (30) | — | — | 26 | (1) | |||||||||||||||||||||||||||||
Total net (loss) income | $ | 28 | $ | (30) | $ | — | $ | — | $ | 3 | $ | 14 | |||||||||||||||||||||||
Three Months Ended | |||||||||||||||||||||||||||||||||||
March 31, 2023 | |||||||||||||||||||||||||||||||||||
Stone Point | Monument | AmTrust | Citco | Core Specialty | Other | ||||||||||||||||||||||||||||||
(in millions of U.S. dollars) | |||||||||||||||||||||||||||||||||||
REVENUES | |||||||||||||||||||||||||||||||||||
Net investment income | 5 | — | 2 | — | — | 2 | |||||||||||||||||||||||||||||
Net realized gains | 1 | — | — | — | — | — | |||||||||||||||||||||||||||||
Fair value changes in trading securities, funds held and other investments | 14 | — | (2) | — | — | 44 | |||||||||||||||||||||||||||||
Total revenues | 20 | — | — | — | — | 46 | |||||||||||||||||||||||||||||
EXPENSES | |||||||||||||||||||||||||||||||||||
Net incurred losses and LAE | — | — | — | — | (10) | — | |||||||||||||||||||||||||||||
Total expenses | — | — | — | — | (10) | — | |||||||||||||||||||||||||||||
(Loss) income from equity method investments | — | (1) | — | 1 | 11 | — | |||||||||||||||||||||||||||||
Total net income (loss) | $ | 20 | $ | (1) | $ | — | $ | 1 | $ | 21 | $ | 46 | |||||||||||||||||||||||
Section | Page | |||||||
Consolidated Results of Operations — for the Three Months Ended March 31, 2024 and 2023 | ||||||||
Results of Operations by Segment — for the Three Months Ended March 31, 2024 and 2023 | ||||||||
Three Months Ended | |||||||||||||||||
March 31, | $ / pp Change | ||||||||||||||||
2024 | 2023 | ||||||||||||||||
(in millions of U.S. dollars, except per share data) | |||||||||||||||||
Technical Results | |||||||||||||||||
Net premiums earned | $ | 11 | $ | 8 | $ | 3 | |||||||||||
Net incurred losses and LAE | |||||||||||||||||
Current period | 5 | 10 | (5) | ||||||||||||||
Prior period | (24) | (10) | (14) | ||||||||||||||
Total net incurred losses and LAE | (19) | — | (19) | ||||||||||||||
Acquisition costs | 1 | 2 | (1) | ||||||||||||||
Investment Results | |||||||||||||||||
Net investment income | 160 | 156 | 4 | ||||||||||||||
Net realized losses | (6) | (18) | 12 | ||||||||||||||
Fair value changes in trading securities, funds held and other investments | 85 | 206 | (121) | ||||||||||||||
(Loss) income from equity method investments | (5) | 11 | (16) | ||||||||||||||
Other income | — | 280 | (280) | ||||||||||||||
Amortization of net deferred charge assets | 30 | 17 | 13 | ||||||||||||||
General and administrative expenses | 87 | 89 | (2) | ||||||||||||||
NET INCOME | 128 | 519 | (391) | ||||||||||||||
Net income attributable to noncontrolling interests | — | (86) | 86 | ||||||||||||||
NET INCOME ATTRIBUTABLE TO ENSTAR ORDINARY SHAREHOLDERS | $ | 119 | $ | 424 | $ | (305) | |||||||||||
COMPREHENSIVE INCOME ATTRIBUTABLE TO ENSTAR | $ | 100 | $ | 239 | $ | (139) | |||||||||||
GAAP measures: | |||||||||||||||||
ROE | 2.4 | % | 9.5 | % | (7.1) | pp | |||||||||||
Annualized ROE | 9.5 | % | 38.0 | % | (28.5) | pp | |||||||||||
Annualized TIR | 4.9 | % | 9.5 | % | (4.6) | pp | |||||||||||
RLE | 0.2 | % | 0.1 | % | 0.1 | pp | |||||||||||
Non-GAAP measures: | |||||||||||||||||
Adjusted ROE* | 2.6 | % | 6.8 | % | (4.2) | pp | |||||||||||
Annualized Adjusted ROE* | 10.5 | % | 27.3 | % | (16.8) | pp | |||||||||||
Annualized Adjusted TIR* | 5.5 | % | 6.3 | % | (0.8) | pp | |||||||||||
Adjusted RLE * | 0.2 | % | 0.3 | % | (0.1) | pp | |||||||||||
As of | $ Change | ||||||||||||||||
March 31, 2024 | December 31, 2023 | ||||||||||||||||
GAAP measure: | |||||||||||||||||
BVPS | $ | 349.41 | $ | 343.45 | $ | 5.96 | |||||||||||
Non-GAAP measure: | |||||||||||||||||
Fully diluted BVPS* | $ | 341.53 | $ | 336.72 | $ | 4.81 |
BVPS and Fully Diluted BVPS* increased by 1.7% and 1.4%, respectively, from December 31, 2023 to March 31, 2024, primarily as a result of comprehensive income attributable to Enstar of $100 million. The cumulative unrealized loss and fair value changes in our fixed maturities portfolio and funds held was $789 million as of March 31, 2024, which adversely impacted BVPS by $53.82 per share and FDBVPS* by $52.61 per share. |
Three Months Ended March 31, | |||||||||||||||||||||||||||||||||||
2024 | 2023 | ||||||||||||||||||||||||||||||||||
Run-off | Corporate and other | Total | Run-off | Corporate and other | Total | ||||||||||||||||||||||||||||||
(in millions of U.S. dollars) | |||||||||||||||||||||||||||||||||||
Net premiums earned | $ | 11 | $ | — | $ | 11 | $ | 8 | $ | — | $ | 8 | |||||||||||||||||||||||
Net incurred losses and LAE: | |||||||||||||||||||||||||||||||||||
Current period | 5 | — | 5 | 10 | — | 10 | |||||||||||||||||||||||||||||
Prior periods | (23) | (1) | (24) | (33) | 23 | (10) | |||||||||||||||||||||||||||||
Total net incurred losses and LAE | (18) | (1) | (19) | (23) | 23 | — | |||||||||||||||||||||||||||||
Acquisition costs | 1 | — | 1 | 2 | — | 2 | |||||||||||||||||||||||||||||
Technical results | $ | 28 | $ | 1 | $ | 29 | $ | 29 | $ | (23) | $ | 6 |
Three Months Ended March 31, 2024 | |||||||||||||||||||||||||||||||||||
RLE | Adjusted RLE* | ||||||||||||||||||||||||||||||||||
Acquisition Year | RLE / PPD | Average net loss reserves | RLE % | Adjusted RLE / PPD* | Average adjusted net loss reserves* | Adjusted RLE %* | |||||||||||||||||||||||||||||
(in millions of U.S. dollars) | |||||||||||||||||||||||||||||||||||
2014 and prior | $ | (12) | $ | 1,274 | $ | (8) | $ | 939 | |||||||||||||||||||||||||||
2015 | 1 | 412 | 1 | 237 | |||||||||||||||||||||||||||||||
2016 | 5 | 581 | 5 | 643 | |||||||||||||||||||||||||||||||
2017 | (3) | 571 | (8) | 784 | |||||||||||||||||||||||||||||||
2018 | (11) | 762 | (9) | 614 | |||||||||||||||||||||||||||||||
2019 | (3) | 653 | (3) | 1,450 | |||||||||||||||||||||||||||||||
2020 | (12) | 1,667 | (12) | 367 | |||||||||||||||||||||||||||||||
2021 | 39 | 2,551 | 38 | 3,207 | |||||||||||||||||||||||||||||||
2022 | 19 | 1,826 | 19 | 2,164 | |||||||||||||||||||||||||||||||
2023 | 1 | 909 | 1 | 1,706 | |||||||||||||||||||||||||||||||
Total | $ | 24 | $ | 11,206 | 0.2 | % | $ | 24 | $ | 12,111 | 0.2 | % |
Three Months Ended March 31, 2023 | |||||||||||||||||||||||||||||||||||
RLE | Adjusted RLE* | ||||||||||||||||||||||||||||||||||
Acquisition Year | RLE / PPD | Average net loss reserves | RLE % | Adjusted RLE / PPD* | Average adjusted net loss reserves* | Adjusted RLE %* | |||||||||||||||||||||||||||||
(in millions of U.S. dollars) | |||||||||||||||||||||||||||||||||||
2014 and prior | $ | 9 | $ | 1,263 | $ | 7 | $ | 772 | |||||||||||||||||||||||||||
2015 | 1 | 287 | 1 | 305 | |||||||||||||||||||||||||||||||
2016 | — | 681 | 2 | 750 | |||||||||||||||||||||||||||||||
2017 | (12) | 573 | 1 | 799 | |||||||||||||||||||||||||||||||
2018 | (10) | 745 | (2) | 833 | |||||||||||||||||||||||||||||||
2019 | (1) | 1,047 | — | 1,576 | |||||||||||||||||||||||||||||||
2020 | 13 | 562 | 14 | 565 | |||||||||||||||||||||||||||||||
2021 | 7 | 3,394 | 10 | 3,881 | |||||||||||||||||||||||||||||||
2022 | 3 | 3,067 | 3 | 3,073 | |||||||||||||||||||||||||||||||
Total | $ | 10 | $ | 11,619 | 0.1 | % | $ | 36 | $ | 12,554 | 0.3 | % |
Three Months Ended March 31, | |||||||||||||||||||||||||||||||||||
2024 | 2023 | ||||||||||||||||||||||||||||||||||
Fixed Income | Other Investments | Total | Fixed Income | Other Investments | Total | ||||||||||||||||||||||||||||||
(in millions of U.S. dollars) | |||||||||||||||||||||||||||||||||||
Net investment income | $ | 140 | $ | 20 | $ | 160 | $ | 132 | $ | 24 | $ | 156 | |||||||||||||||||||||||
Net realized losses | (6) | — | (6) | (18) | — | (18) | |||||||||||||||||||||||||||||
Fair value changes in trading securities, funds held and other investments | (19) | 104 | 85 | 59 | 147 | 206 | |||||||||||||||||||||||||||||
(Loss) income from equity method investments | — | (5) | (5) | — | 11 | 11 | |||||||||||||||||||||||||||||
Other comprehensive income: | |||||||||||||||||||||||||||||||||||
Unrealized (losses) gains on fixed maturities, AFS, net of reclassification adjustments, excluding foreign exchange | (12) | — | (12) | 87 | — | 87 | |||||||||||||||||||||||||||||
TIR ($) | $ | 103 | $ | 119 | $ | 222 | $ | 260 | $ | 182 | $ | 442 | |||||||||||||||||||||||
Annualized TIR % | 3.2 | % | 9.5 | % | 4.9 | % | 7.6 | % | 14.7 | % | 9.5 | % | |||||||||||||||||||||||
Annualized Adjusted TIR %* | 4.1 | % | 9.5 | % | 5.5 | % | 3.5 | % | 14.7 | % | 6.3 | % |
March 31, 2024 | December 31, 2023 | |||||||||||||||||||||||||||||||||||||
Fair Value ($) (1) | Average Duration (in years) (2) | Average Credit Rating (3) | Fair Value ($) (1) | Average Duration (in years) (2) | Average Credit Rating (3) | |||||||||||||||||||||||||||||||||
Total | $ | 9,733 | 3.91 | A+ | $ | 10,320 | 4.04 | A+ |
Non-GAAP Measure | Definition | Purpose of Non-GAAP Measure over GAAP Measure | ||||||||||||
Fully diluted book value per ordinary share | Total Enstar ordinary shareholders' equity Divided by Number of ordinary shares outstanding, adjusted for: -the ultimate effect of any dilutive securities (which include restricted shares, restricted share units, directors’ restricted share units and performance share units) on the number of ordinary shares outstanding | Increases the number of ordinary shares to reflect the exercise of equity awards granted but not yet vested as, over the long term, this presents both management and investors with a more economically accurate measure of the realizable value of shareholder returns by factoring in the impact of share dilution. We use this non-GAAP measure in our incentive compensation program. |
Adjusted return on equity (%) | Adjusted operating income (loss) attributable to Enstar ordinary shareholders divided by adjusted opening Enstar ordinary shareholder's equity | Calculating the operating income (loss) as a percentage of our adjusted opening Enstar ordinary shareholders' equity provides a more consistent measure of the performance of our business by enabling comparison between the financial periods presented. We eliminate the impact of fair value changes and net realized (gains) losses on fixed maturities and funds held-directly managed and the change in fair value of insurance contracts for which we have elected the fair value option, as: •we typically hold most of our fixed maturities until the earlier of maturity or the time that they are used to fund any settlement of related liabilities which are generally recorded at cost; and •removing the fair value option improves comparability since there are limited acquisition years for which we elected the fair value option. Therefore, we believe that excluding their impact on our net income improves comparability of our core operational performance across periods. We include fair value adjustments as non-GAAP adjustments to the adjusted operating income (loss) attributable to Enstar ordinary shareholders as they are non-cash charges that are not reflective of the impact of our claims management strategies on our loss portfolios. We eliminate the net gain (loss) on the purchase and sales of subsidiaries and net income from discontinued operations, as these items are not indicative of our ongoing operations. We use this non-GAAP measure in our incentive compensation program. | ||||||||||||
Adjusted operating income (loss) attributable to Enstar ordinary shareholders (numerator) | Net income (loss) attributable to Enstar ordinary shareholders, adjusted for: -fair value changes and net realized (gains) losses on fixed maturities and funds held-directly managed, -change in fair value of insurance contracts for which we have elected the fair value option (1), -amortization of fair value adjustments, -net gain/loss on purchase and sales of subsidiaries (if any), -net income from discontinued operations (if any), -tax effects of adjustments, and -adjustments attributable to noncontrolling interests | |||||||||||||
Adjusted opening Enstar ordinary shareholders' equity (denominator) | Opening Enstar ordinary shareholders' equity, less: -fair value changes on fixed maturities and funds held-directly managed, -fair value of insurance contracts for which we have elected the fair value option (1), -fair value adjustments, and -net assets of held for sale or disposed subsidiaries classified as discontinued operations (if any) |
Adjusted run-off liability earnings (%) | Adjusted PPD divided by average adjusted net loss reserves. | Calculating the RLE as a percentage of our adjusted average net loss reserves provides a more meaningful and comparable measurement of the impact of our claims management strategies on our loss portfolios across acquisition years and also to our overall financial periods. We use this measure to evaluate the impact of our claims management strategies because it provides visibility into our ability to settle our claims obligations for amounts less than our initial estimate at the point of acquiring the obligations. The following components of periodic recurring net incurred losses and LAE and net loss reserves are not considered key components of our claims management performance for the following reasons: •Prior to the settlement of the contractual arrangements, the results of our Legacy Underwriting segment were economically transferred to a third party primarily through use of reinsurance and a Capacity Lease Agreement(3); as such, the results were not a relevant contribution to Adjusted RLE, which is designed to analyze the impact of our claims management strategies(2); •The change in fair value of insurance contracts for which we have elected the fair value option(1) has been removed to support comparability between the two acquisition years for which we elected the fair value option in reserves assumed and the acquisition years for which we did not make this election (specifically, this election was only made in the 2017 and 2018 acquisition years and the election of such option is irrevocable); and •The amortization of fair value adjustments are non-cash charges that obscure our trends on a consistent basis. We include our performance in managing claims and estimated future expenses on our defendant A&E liabilities because such performance is relevant to assessing our claims management strategies even though such liabilities are not included within the loss reserves. We use this measure to assess the performance of our claim strategies and part of the performance assessment of our past acquisitions. | ||||||||||||
Adjusted prior period development (numerator) | Prior period net incurred losses and LAE, adjusted to: Remove: -Legacy Underwriting(2) operations -amortization of fair value adjustments, -change in fair value of insurance contracts for which we have elected the fair value option (1), and Add: -the reduction/(increase) in estimates of net ultimate liabilities and reduction in estimated future expenses of our defendant A&E liabilities. | |||||||||||||
Adjusted net loss reserves (denominator) | Net losses and LAE, adjusted to: Remove: -Legacy Underwriting(2) net loss reserves -current period net loss reserves -net fair value adjustments associated with the acquisition of companies, -the fair value adjustments for contracts for which we have elected the fair value option (1) and Add: -net nominal defendant A&E liability exposures and estimated future expenses. | |||||||||||||
Adjusted total investment return (%) | Adjusted total investment return (dollars) recognized in net income for the applicable period divided by period average adjusted total investable assets. | Provides a key measure of the return generated on the capital held in the business and is reflective of our investment strategy. Provides a consistent measure of investment returns as a percentage of all assets generating investment returns. We adjust our investment returns to eliminate the impact of the change in fair value of fixed maturities (both credit spreads and interest rates), as we typically hold most of these investments until the earlier of maturity or used to fund any settlement of related liabilities which are generally recorded at cost. | ||||||||||||
Adjusted total investment return ($) (numerator) | Total investment return (dollars), adjusted for: -fair value changes in fixed maturities, trading and funds held-directly managed; and -unrealized (gains) losses on fixed maturities, AFS included within OCI, net of reclassification adjustments and excluding foreign exchange. | |||||||||||||
Adjusted average aggregate total investable assets (denominator) | Total average investable assets, adjusted for: -net unrealized (gains) losses on fixed maturities, AFS included within AOCI -fair value changes on fixed maturities, trading and funds held - directly managed | |||||||||||||
March 31, 2024 | December 31, 2023 | ||||||||||||||||||||||||||||||||||
Equity (1) | Ordinary Shares | Per Share Amount | Equity (1) | Ordinary Shares | Per Share Amount | ||||||||||||||||||||||||||||||
(in millions of U.S. dollars, except share and per share data) | |||||||||||||||||||||||||||||||||||
Book value per ordinary share | $ | 5,122 | 14,658,801 | $ | 349.41 | $ | 5,025 | 14,631,055 | $ | 343.45 | |||||||||||||||||||||||||
Non-GAAP adjustment: | |||||||||||||||||||||||||||||||||||
Share-based compensation plans | 338,576 | 292,190 | |||||||||||||||||||||||||||||||||
Fully diluted book value per ordinary share* | $ | 5,122 | 14,997,377 | $ | 341.53 | $ | 5,025 | 14,923,245 | $ | 336.72 | |||||||||||||||||||||||||
Three Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||
March 31, 2024 | March 31, 2023 | ||||||||||||||||||||||||||||||||||||||||||||||
Net income (loss) (1) | Opening equity (1) | (Adj) ROE | Annualized (Adj) ROE | Net income (loss) (1) | Opening equity (1) | (Adj) ROE | Annualized (Adj) ROE | ||||||||||||||||||||||||||||||||||||||||
(in millions of U.S. dollars) | |||||||||||||||||||||||||||||||||||||||||||||||
Net income/Opening equity/ROE/Annualized ROE (1) | $ | 119 | $ | 5,025 | 2.4 | % | 9.5 | % | $ | 424 | $ | 4,464 | 9.5 | % | 38.0 | % | |||||||||||||||||||||||||||||||
Non-GAAP adjustments for loss (gains): | |||||||||||||||||||||||||||||||||||||||||||||||
Net realized losses on fixed maturities, AFS (2) / Cumulative fair value changes to fixed maturities, AFS (3) | 6 | 380 | 18 | 647 | |||||||||||||||||||||||||||||||||||||||||||
Fair value changes on fixed maturities, trading (2) / Fair value changes on fixed maturities, trading (3) | 14 | 234 | (40) | 400 | |||||||||||||||||||||||||||||||||||||||||||
Fair value changes on funds held - directly managed (2) / Fair value changes on funds held - directly managed (3) | 5 | 111 | (19) | 780 | |||||||||||||||||||||||||||||||||||||||||||
Change in fair value of insurance contracts for which we have elected the fair value option / Fair value of insurance contracts for which we have elected the fair value option (4) | (4) | (246) | 20 | (294) | |||||||||||||||||||||||||||||||||||||||||||
Amortization of fair value adjustments / Fair value adjustments | 3 | (107) | 3 | (124) | |||||||||||||||||||||||||||||||||||||||||||
Tax effects of adjustments (5) | (2) | — | (3) | — | |||||||||||||||||||||||||||||||||||||||||||
Adjustments attributable to noncontrolling interests (6) | — | — | (2) | — | |||||||||||||||||||||||||||||||||||||||||||
Adjusted net income (loss)/Adjusted opening equity/Adjusted ROE/Annualized adjusted ROE* | $ | 141 | $ | 5,397 | 2.6 | % | 10.5 | % | $ | 401 | $ | 5,873 | 6.8 | % | 27.3 | % |
Three Months Ended | As of | Three Months Ended | |||||||||||||||||||||||||||
March 31, 2024 | March 31, 2024 | December 31, 2023 | March 31, 2024 | March 31, 2024 | |||||||||||||||||||||||||
RLE / PPD | Net loss reserves | Net loss reserves | Average net loss reserves | RLE % | |||||||||||||||||||||||||
(in millions of U.S. dollars) | |||||||||||||||||||||||||||||
PPD/net loss reserves/RLE % | $ | 24 | $ | 10,827 | $ | 11,585 | $ | 11,206 | 0.2 | % | |||||||||||||||||||
Non-GAAP adjustments for expenses (income): | |||||||||||||||||||||||||||||
Net loss reserves incurred in the current period | — | (5) | — | (3) | |||||||||||||||||||||||||
Amortization of fair value adjustments / Net fair value adjustments associated with the acquisition of companies | 3 | 103 | 107 | 105 | |||||||||||||||||||||||||
Changes in fair value - fair value option / Net fair value adjustments for contracts for which we have elected the fair value option (1) | (4) | 249 | 246 | 248 | |||||||||||||||||||||||||
Change in estimate of net ultimate liabilities - defendant A&E / Net nominal defendant A&E liabilities | — | 516 | 527 | 522 | |||||||||||||||||||||||||
Reduction in estimated future expenses - defendant A&E / Estimated future expenses - defendant A&E | 1 | 32 | 33 | 33 | |||||||||||||||||||||||||
Adjusted PPD/Adjusted net loss reserves/Adjusted RLE %* | $ | 24 | $ | 11,722 | $ | 12,498 | $ | 12,111 | 0.2 | % |
Three Months Ended | As of | Three Months Ended | |||||||||||||||||||||||||||
March 31, 2023 | March 31, 2023 | December 31, 2022 | March 31, 2023 | March 31, 2023 | |||||||||||||||||||||||||
RLE / PPD | Net loss reserves | Net loss reserves | Average net loss reserves | RLE % | |||||||||||||||||||||||||
(in millions of U.S. dollars) | |||||||||||||||||||||||||||||
PPD/net loss reserves/RLE % | $ | 10 | $ | 11,226 | $ | 12,011 | $ | 11,619 | 0.1 | % | |||||||||||||||||||
Non-GAAP adjustments for expenses (income): | |||||||||||||||||||||||||||||
Net loss reserves incurred in the current period | — | (9) | — | (5) | |||||||||||||||||||||||||
Legacy Underwriting | — | — | (139) | (70) | |||||||||||||||||||||||||
Amortization of fair value adjustments / Net fair value adjustments associated with the acquisition of companies | 3 | 121 | 124 | 123 | |||||||||||||||||||||||||
Changes in fair value - fair value option / Net fair value adjustments for contracts for which we have elected the fair value option (1) | 20 | 278 | 294 | 286 | |||||||||||||||||||||||||
Change in estimate of net ultimate liabilities - defendant A&E / Net nominal defendant A&E liabilities | 2 | 560 | 572 | 566 | |||||||||||||||||||||||||
Reduction in estimated future expenses - defendant A&E / Estimated future expenses - defendant A&E | 1 | 34 | 35 | 35 | |||||||||||||||||||||||||
Adjusted PPD/Adjusted net loss reserves/Adjusted RLE %* | $ | 36 | $ | 12,210 | $ | 12,897 | $ | 12,554 | 0.3 | % |
Three Months Ended | |||||||||||||||||||||||||||||||||||
March 31, | |||||||||||||||||||||||||||||||||||
2024 | 2023 | ||||||||||||||||||||||||||||||||||
Fixed Income | Other Investments | Total | Fixed Income | Other Investments | Total | ||||||||||||||||||||||||||||||
(in millions of U.S. dollars) | |||||||||||||||||||||||||||||||||||
Net investment income | $ | 140 | $ | 20 | $ | 160 | $ | 132 | $ | 24 | $ | 156 | |||||||||||||||||||||||
Net realized losses | |||||||||||||||||||||||||||||||||||
Fixed maturities, AFS | (6) | — | (6) | (18) | — | (18) | |||||||||||||||||||||||||||||
Net realized losses | (6) | — | (6) | (18) | — | (18) | |||||||||||||||||||||||||||||
Fair value changes | |||||||||||||||||||||||||||||||||||
Fixed maturities, trading | (14) | — | (14) | 40 | — | 40 | |||||||||||||||||||||||||||||
Funds held | (5) | — | (5) | 19 | — | 19 | |||||||||||||||||||||||||||||
Equity securities | — | 37 | 37 | — | 53 | 53 | |||||||||||||||||||||||||||||
Other investments | — | 67 | 67 | — | 85 | 85 | |||||||||||||||||||||||||||||
Investment derivatives | — | — | — | — | 9 | 9 | |||||||||||||||||||||||||||||
Fair value changes | (19) | 104 | 85 | 59 | 147 | 206 | |||||||||||||||||||||||||||||
(Loss) income from equity method investments | — | (5) | (5) | — | 11 | 11 | |||||||||||||||||||||||||||||
Other comprehensive income: | |||||||||||||||||||||||||||||||||||
Unrealized (losses) gains on fixed maturities, AFS, net of reclassification adjustments excluding foreign exchange | (12) | — | (12) | 87 | — | 87 | |||||||||||||||||||||||||||||
TIR ($) | $ | 103 | $ | 119 | $ | 222 | $ | 260 | $ | 182 | $ | 442 | |||||||||||||||||||||||
Non-GAAP adjustments: | |||||||||||||||||||||||||||||||||||
Net realized losses (gains) on fixed maturities, AFS and fair value changes in trading and funds held - directly managed | 25 | — | 25 | (41) | — | (41) | |||||||||||||||||||||||||||||
Net unrealized losses (gains) on fixed maturities, AFS, net of reclassification adjustments excluding foreign exchange | 12 | — | 12 | (87) | — | (87) | |||||||||||||||||||||||||||||
Adjusted TIR ($)* | $ | 140 | $ | 119 | $ | 259 | $ | 132 | $ | 182 | $ | 314 | |||||||||||||||||||||||
Total investments | $ | 11,835 | $ | 5,082 | $ | 16,917 | $ | 11,725 | $ | 4,905 | $ | 16,630 | |||||||||||||||||||||||
Cash and cash equivalents, including restricted cash and cash equivalents | 760 | — | 760 | 1,143 | — | 1,143 | |||||||||||||||||||||||||||||
Total investable assets | $ | 12,595 | $ | 5,082 | $ | 17,677 | $ | 12,868 | $ | 4,905 | $ | 17,773 | |||||||||||||||||||||||
Average aggregate invested assets, at fair value (1) | 13,035 | 4,986 | 18,021 | 13,676 | 4,939 | 18,615 | |||||||||||||||||||||||||||||
Annualized TIR % (2) | 3.2 | % | 9.5 | % | 4.9 | % | 7.6 | % | 14.7 | % | 9.5 | % | |||||||||||||||||||||||
Non-GAAP adjustment: | |||||||||||||||||||||||||||||||||||
Net unrealized losses on fixed maturities, AFS included within AOCI and fair value changes on fixed maturities, trading and funds held - directly managed | 789 | — | 789 | 994 | — | 994 | |||||||||||||||||||||||||||||
Adjusted investable assets* | $ | 13,384 | $ | 5,082 | $ | 18,466 | $ | 13,862 | $ | 4,905 | $ | 18,767 | |||||||||||||||||||||||
Adjusted average aggregate invested assets, at fair value* (3) | $ | 13,792 | $ | 4,986 | $ | 18,778 | $ | 15,081 | $ | 4,939 | $ | 20,020 | |||||||||||||||||||||||
Annualized adjusted TIR %* (4) | 4.1 | % | 9.5 | % | 5.5 | % | 3.5 | % | 14.7 | % | 6.3 | % | |||||||||||||||||||||||
Annualized income from fixed income assets (5) | 600 | — | 600 | 544 | — | 544 | |||||||||||||||||||||||||||||
Average aggregate fixed income assets, at cost (5)(6) | 13,769 | — | 13,769 | 15,199 | — | 15,199 | |||||||||||||||||||||||||||||
Annualized Investment book yield (7) | 4.36 | % | — | % | 4.36 | % | 3.58 | % | — | % | 3.58 | % |
Three Months Ended | |||||||||||||||||
March 31, | $ Change | ||||||||||||||||
2024 | 2023 | ||||||||||||||||
REVENUES | (in millions of U.S. dollars) | ||||||||||||||||
Net premiums earned | $ | 11 | $ | 8 | $ | 3 | |||||||||||
Other income: | |||||||||||||||||
Reduction in estimates of net ultimate defendant A&E liabilities - prior periods | — | 2 | (2) | ||||||||||||||
Reduction in estimated future defendant A&E expenses | 1 | 1 | — | ||||||||||||||
All other income | 2 | 2 | — | ||||||||||||||
Total other income | 3 | 5 | (2) | ||||||||||||||
Total revenues | 14 | 13 | 1 | ||||||||||||||
EXPENSES | |||||||||||||||||
Net incurred losses and LAE: | |||||||||||||||||
Current period | 5 | 10 | (5) | ||||||||||||||
Prior periods: | |||||||||||||||||
Reduction in estimates of net ultimate losses | (6) | (15) | 9 | ||||||||||||||
Reduction in provisions for ULAE | (17) | (18) | 1 | ||||||||||||||
Total prior periods | (23) | (33) | 10 | ||||||||||||||
Total net incurred losses and LAE | (18) | (23) | 5 | ||||||||||||||
Acquisition costs | 1 | 2 | (1) | ||||||||||||||
General and administrative expenses | 42 | 39 | 3 | ||||||||||||||
Total expenses | 25 | 18 | 7 | ||||||||||||||
SEGMENT NET LOSS | $ | (11) | $ | (5) | $ | (6) | |||||||||||
Three Months Ended | |||||||||||||||||
March 31, | $ Change | ||||||||||||||||
2024 | 2023 | ||||||||||||||||
(in millions of U.S. dollars) | |||||||||||||||||
REVENUES | |||||||||||||||||
Net investment income: | |||||||||||||||||
Fixed maturities | $ | 142 | $ | 131 | $ | 11 | |||||||||||
Cash and restricted cash | 8 | 5 | 3 | ||||||||||||||
Other investments, including equities | 20 | 24 | (4) | ||||||||||||||
Less: Investment expenses | (10) | (4) | (6) | ||||||||||||||
Total net investment income | 160 | 156 | 4 | ||||||||||||||
Net realized losses: | |||||||||||||||||
Fixed maturities | (6) | (18) | 12 | ||||||||||||||
Total net realized losses | (6) | (18) | 12 | ||||||||||||||
Fair value changes in: | |||||||||||||||||
Fixed maturities, trading | (19) | 59 | (78) | ||||||||||||||
Other investments, including equities | 104 | 147 | (43) | ||||||||||||||
Total fair value changes in trading securities and other investments | 85 | 206 | (121) | ||||||||||||||
Total revenues | 239 | 344 | (105) | ||||||||||||||
EXPENSES | |||||||||||||||||
General and administrative expenses | 10 | 11 | (1) | ||||||||||||||
Total expenses | 10 | 11 | (1) | ||||||||||||||
(Loss) income from equity method investments | (5) | 11 | (16) | ||||||||||||||
SEGMENT NET INCOME | $ | 224 | $ | 344 | $ | (120) |
March 31, 2024 | December 31, 2023 | ||||||||||||||||||||||||||||||||||||||||||||||
Fair Value | % | Duration (years) (1) | Credit Rating (1) | Fair Value | % | Duration (years) (1) | Credit Rating (1) | ||||||||||||||||||||||||||||||||||||||||
(in millions of U.S. dollars, except percentages) | |||||||||||||||||||||||||||||||||||||||||||||||
Fixed maturity and short-term investments, trading and AFS | |||||||||||||||||||||||||||||||||||||||||||||||
U.S. government & agency | $ | 291 | 3.2 | % | 4.8 | AA+ | $ | 326 | 3.4 | % | 4.5 | AA+ | |||||||||||||||||||||||||||||||||||
U.K. government | 60 | 0.7 | % | 10.5 | A+ | 72 | 0.8 | % | 10.3 | A+ | |||||||||||||||||||||||||||||||||||||
Other government | 364 | 4.1 | % | 4.9 | AA | 391 | 4.1 | % | 5.0 | AA | |||||||||||||||||||||||||||||||||||||
Corporate | 3,927 | 43.7 | % | 5.3 | A- | 4,131 | 43.5 | % | 5.4 | A- | |||||||||||||||||||||||||||||||||||||
Municipal | 132 | 1.5 | % | 7.0 | AA- | 142 | 1.5 | % | 7.6 | AA- | |||||||||||||||||||||||||||||||||||||
Residential mortgage-backed | 465 | 5.2 | % | 5.1 | AA | 487 | 5.1 | % | 5.2 | AA | |||||||||||||||||||||||||||||||||||||
Commercial mortgage-backed | 856 | 9.5 | % | 1.5 | AA- | 841 | 8.9 | % | 1.6 | AA- | |||||||||||||||||||||||||||||||||||||
Asset-backed | 860 | 9.6 | % | 1.2 | A | 884 | 9.3 | % | 1.0 | A | |||||||||||||||||||||||||||||||||||||
Total - Fixed maturity and short-term investments, trading and AFS | 6,955 | 77.5 | % | 4.4 | A | 7,274 | 76.6 | % | 4.5 | A | |||||||||||||||||||||||||||||||||||||
Fixed maturities included in funds held - directly managed | 2,019 | 22.5 | % | 4.2 | A | 2,216 | 23.4 | % | 4.3 | A | |||||||||||||||||||||||||||||||||||||
$ | 8,974 | 100.0 | % | 4.3 | A | $ | 9,490 | 100.0 | % | 4.4 | A | ||||||||||||||||||||||||||||||||||||
March 31, 2024 | December 31, 2023 | ||||||||||
(in millions of U.S. dollars) | |||||||||||
Equities | |||||||||||
Publicly traded equities | $ | 310 | $ | 275 | |||||||
Exchange-traded funds | 84 | 82 | |||||||||
Privately held equities | 344 | 344 | |||||||||
Total | $ | 738 | $ | 701 | |||||||
Other investments | |||||||||||
Hedge funds | $ | 559 | $ | 491 | |||||||
Fixed income funds | 550 | 605 | |||||||||
Equity funds | 4 | 4 | |||||||||
Private equity funds | 1,706 | 1,617 | |||||||||
CLO equities | 60 | 60 | |||||||||
CLO equity funds | 161 | 182 | |||||||||
Private credit funds | 642 | 625 | |||||||||
Real estate debt funds | 336 | 269 | |||||||||
Total | $ | 4,018 | $ | 3,853 |
As of | Three Months Ended | As of | Three Months Ended | |||||||||||||||||||||||||||||||||||
March 31, 2024 | March 31, 2024 | December 31, 2023 | March 31, 2023 | |||||||||||||||||||||||||||||||||||
Ownership % | Carrying Value | Income (loss) from Equity Method Investments | Ownership % | Carrying Value | Income (loss) from Equity Method Investments | |||||||||||||||||||||||||||||||||
(in millions of U.S. dollars) | ||||||||||||||||||||||||||||||||||||||
Citco (1) | — | % | $ | — | $ | — | — | % | $ | — | $ | 1 | ||||||||||||||||||||||||||
Monument Re (2) | 24.6 | % | 63 | (30) | 20.0 | % | 95 | (1) | ||||||||||||||||||||||||||||||
Core Specialty | 19.9 | % | 251 | 26 | 19.9 | % | 225 | 11 | ||||||||||||||||||||||||||||||
Other | 27.0 | % | 12 | (1) | 27.0 | % | 14 | — | ||||||||||||||||||||||||||||||
$ | 326 | $ | (5) | $ | 334 | $ | 11 |
Three Months Ended | |||||||||||||||||
March 31, | $ Change | ||||||||||||||||
2024 | 2023 | ||||||||||||||||
REVENUES | (in millions of U.S. dollars) | ||||||||||||||||
Other income: | |||||||||||||||||
Amortization of fair value adjustments (1) | $ | (4) | $ | (4) | $ | — | |||||||||||
All other income | 1 | 4 | (3) | ||||||||||||||
Total revenues | (3) | — | (3) | ||||||||||||||
EXPENSES | |||||||||||||||||
Net incurred losses and LAE - prior periods: | |||||||||||||||||
Amortization of fair value adjustments | 3 | 3 | — | ||||||||||||||
Changes in fair value - fair value option (2) | (4) | 20 | (24) | ||||||||||||||
Total net incurred losses and LAE - prior periods | (1) | 23 | (24) | ||||||||||||||
Amortization of net deferred charge assets | 30 | 17 | 13 | ||||||||||||||
General and administrative expenses | 35 | 39 | (4) | ||||||||||||||
Total expenses | 64 | 79 | (15) | ||||||||||||||
Interest expense | (22) | (23) | 1 | ||||||||||||||
Net foreign exchange gains | 9 | 6 | 3 | ||||||||||||||
Income tax (expense) benefit | (5) | 1 | (6) | ||||||||||||||
Net income attributable to noncontrolling interests | — | (86) | 86 | ||||||||||||||
Dividends on preferred shares | (9) | (9) | — | ||||||||||||||
NET LOSS ATTRIBUTABLE TO ENSTAR ORDINARY SHAREHOLDERS | $ | (94) | $ | (190) | $ | 96 |
Analysis of Sources and Uses of Cash | |||||||||||||||||
Three Months Ended March 31, | |||||||||||||||||
2024 | 2023 | $ Change | |||||||||||||||
(in millions of U.S. dollars) | |||||||||||||||||
Operating Cash Flow Activities | |||||||||||||||||
Net paid losses | $ | (670) | $ | (677) | $ | 7 | |||||||||||
Net sales and maturities of trading securities | 66 | 323 | (257) | ||||||||||||||
Net investment income | 161 | 116 | 45 | ||||||||||||||
Cash consideration received for novation | — | 94 | (94) | ||||||||||||||
Other sources | 275 | 214 | 61 | ||||||||||||||
Net cash flows (used in) provided by operating activities | (168) | 70 | (238) | ||||||||||||||
Investing Cash Flow Activities | |||||||||||||||||
Net sales of AFS securities | 184 | 147 | 37 | ||||||||||||||
Net purchases of other investments | (83) | (54) | (29) | ||||||||||||||
Other sources | 1 | 1 | — | ||||||||||||||
Net cash flows provided by investing activities | 102 | 94 | 8 | ||||||||||||||
Financing Cash Flow Activities | |||||||||||||||||
Preferred share dividends | (9) | (9) | — | ||||||||||||||
Share repurchases | — | (340) | 340 | ||||||||||||||
Other | 1 | — | 1 | ||||||||||||||
Net cash flows used in financing activities | $ | (8) | $ | (349) | $ | 341 |
Facility | Origination Date | Term | March 31, 2024 | December 31, 2023 | ||||||||||||||||||||||
(in millions of U.S. dollars) | ||||||||||||||||||||||||||
4.95% Senior Notes due 2029 | May 2019 | 10 years | $ | 496 | $ | 496 | ||||||||||||||||||||
3.10% Senior Notes due 2031 | August 2021 | 10 years | 496 | 496 | ||||||||||||||||||||||
Total Senior Notes | 992 | 992 | ||||||||||||||||||||||||
5.75% Junior Subordinated Notes due 2040 | August 2020 | 20 years | 346 | 345 | ||||||||||||||||||||||
5.50% Junior Subordinated Notes due 2042 | January 2022 | 20 years | 494 | 494 | ||||||||||||||||||||||
Total Junior Subordinated Notes | 840 | 839 | ||||||||||||||||||||||||
Total debt obligations | $ | 1,832 | $ | 1,831 |
Credit ratings (1) | Standard and Poor’s | Fitch Ratings | ||||||||||||
Long-term issuer | BBB+ (Outlook: Stable) | BBB+ (Outlook: Stable) | ||||||||||||
2029 Senior Notes | BBB+ | BBB | ||||||||||||
2031 Senior Notes | BBB | BBB | ||||||||||||
2040 and 2042 Junior Subordinated Notes | BBB- | BBB- | ||||||||||||
Series D and E Preferred Shares | BBB- | BBB- | ||||||||||||
Short-Term | Long-Term | |||||||||||||||||||
Less than 1 Year | More than 1 Year | Total | ||||||||||||||||||
(in millions of U.S. dollars) | ||||||||||||||||||||
Investing Activities | ||||||||||||||||||||
Unfunded investment commitments | $ | 335 | $ | 1,237 | $ | 1,572 | ||||||||||||||
Financing Activities | ||||||||||||||||||||
Letters of credit | $ | — | $ | 1,769 | 1,769 | |||||||||||||||
Exhibit No. | Description | |||||||
Memorandum of Association of Enstar Group Limited (incorporated by reference to Exhibit 3.1 of the Company’s Form 10-K/A filed on May 2, 2011). | ||||||||
Sixth Amended and Restated Bye-Laws of Enstar Group Limited (incorporated by reference to Exhibit 3.1 of the Company’s Form 8-K filed on June 15, 2021). | ||||||||
Certificate of Designations of Series C Participating Non-Voting Perpetual Preferred Stock (incorporated by reference to Exhibit 3.1 of the Company’s Form 8-K filed on June 17, 2016). | ||||||||
Certificate of Designations of 7.00% fixed-to-floating rate perpetual non-cumulative preference shares, Series D (incorporated by reference to Exhibit 4.1 of the Company’s Form 8-K filed on June 27, 2018). | ||||||||
Certificate of Designations of 7.00% perpetual non-cumulative preference shares, Series E (incorporated by reference to Exhibit 4.1 of the Company’s Form 8-K filed on November 21, 2018). | ||||||||
Amended and Restated Employment Agreement, dated June 6, 2023, by and between Enstar (US), Inc. and Nazar Alobaidat. | ||||||||
Amendment No. 2 to the Employment Agreement, dated April 4, 2024, between Enstar (US), Inc. and Paul Brockman. | ||||||||
Contract of Employment, dated April 4, 2024, between Enstar (EU) Limited and Paul Brockman. | ||||||||
31.1* | Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934 as adopted under Section 302 of the Sarbanes-Oxley Act of 2002. | |||||||
31.2* | Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934 as adopted under Section 302 of the Sarbanes-Oxley Act of 2002. | |||||||
32.1** | Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | |||||||
32.2** | Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | |||||||
101.INS | XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. | |||||||
101.SCH | XBRL Taxonomy Extension Schema | |||||||
101.CAL | XBRL Taxonomy Extension Calculation Linkbase | |||||||
101.LAB | XBRL Taxonomy Extension Label Linkbase | |||||||
101.DEF | XBRL Taxonomy Extension Definition Linkbase | |||||||
101.PRE | XBRL Taxonomy Extension Presentation Linkbase | |||||||
104 | Cover page Interactive Data File (embedded within the Inline XBRL document and included in Exhibit 101) |
ENSTAR GROUP LIMITED | |||||
By: | /s/ Matthew Kirk | ||||
Matthew Kirk Chief Financial Officer, Authorized Signatory and Principal Financial Officer | |||||
By: | /s/ Girish Ramanathan | ||||
Girish Ramanathan Chief Accounting Officer and Principal Accounting Officer |
Signed on behalf of Enstar (EU) Limited | /s/ Steven Humberstone Steven Humberstone Chief People Officer |
Signed by Paul Brockman | /s/ Paul Brockman Paul Brockman |
/S/ DOMINIC F. SILVESTER | ||
Dominic F. Silvester | ||
Chief Executive Officer |
/S/ MATTHEW KIRK | ||
Matthew Kirk | ||
Chief Financial Officer |
/S/ DOMINIC F. SILVESTER | ||
Dominic F. Silvester | ||
Chief Executive Officer |
/S/ MATTHEW KIRK | ||
Matthew Kirk | ||
Chief Financial Officer |